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SUMMARY 
 
Oligodendrocytes (ODCs) are glial cells of the central nervous system (CNS), best 
known for the production of myelin which insulates axons. Recent investigations have 
highlighted additional roles of ODCs as the maintenance of axonal integrity, and ODC 
impairment has been associated to several human pathologies stressing the importance 
of these cells in neurodegeneration and in the neuroimmunological interplay. Primary 
ODC death is debated for initiating multiple sclerosis (MS), a pathological condition in 
which inflammation and neurodegeneration sustain the typical progressive clinical 
impairment. To specifically test ODC death as a trigger for anti-CNS immunity in MS, 
we inducibly killed ODCs through diphtheria toxin administration in a transgenic mouse 
model. However, even conditions favoring autoimmunity – bystander activation, 
removal of regulatory T cells, presence of myelin-reactive T cells, and application of 
demyelinating antibodies – did not result in the development of CNS inflammation after 
ODC death. We could thus show that diffuse ODC death alone or in conjunction with 
immune activation is an unlikely trigger of sustained anti-CNS immunity.  
Next, we investigated the relevance of ODC damage in animal models of 
neurodegeneration focusing on the insulin-like growth factor 1 receptor (IGF1R) 
pathway. In MS, surviving ODCs surrounding sclerotic lesions upregulate IGF1R and 
Insulin-like growth factor 1 (IGF-1), indicating a role of this pathway in response to 
inflammatory demyelination. IGF-1 is an anti-apoptotic, myelinogenic stimulus in the 
ODC lineage. In our oIGF1R mouse model, a deletion of this receptor specifically in 
mature ODCs resulted in ameliorated clinical disabilities in the inflammatory model for 
MS, experimental autoimmune encephalomyelitis (EAE), despite increased ODC 
mortality and decreased remyelination capabilities following cuprizone intoxication. 
Hence, we confirmed the anti-apoptotic role of IGF1R in the ODC lineage while 
highlighting a surprising benefit of IGF1R absence from mature ODCs during 
prolonged neuroinflammation. 
Finally, we were interested in creating a mouse model that would allow us to image 
these dynamics of demyelination and remyelination in vivo. Thus, we created the 
oLucR transgenic mouse strain, in which the luciferase reporter gene is specifically 
expressed in mature ODCs under the control of a β-actin promoter. Using oLucR mice 
we were able to observe defined and reproducible increases in the in vivo 
bioluminescence signal at beginning of induced demyelination and CNS inflammation, 
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pointing out the possibility that under demyelinating conditions ODCs might adopt an 
“active phenotype” characterized by renewed cytoskeleton motility. 
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ZUSAMMENFASSUNG 
 
Oligodendrozyten (ODZ) sind Gliazellen. des Zentralen Nervensystems (ZNS), welche 
vor allem zuständig sind für die Produktion des Myelins, welches Axone isoliert. Neue 
Untersuchungen heben allerdings zusätzliche Funktionen der ODZ neben der Erhaltung 
axonaler Integrität hervor. So wurde die Schädigung von ODZ mit einigen 
neuroimmunologischen und -degenerativen Pathologien des ZNS assoziert. Zum 
Beispiel wurde der primäre Tod von ODZ als Trigger der Multiplen Sklerose (MS) 
postuliert, einer ZNS Erkrankung, in der Neuroinflammation und –degeneration 
progrediente klinischen-neurologischen Defizite verursachen. Um die Hypothese zu 
prüfen, dass sterbende ODZ in MS eine gegen das ZNS gerichtete Immunantwort 
auslösen können, haben wir mittels eines transgenen Mausmodells selektiv ODZ durch 
Gabe von Diphtherietoxin geschädigt. Sogar Bedingungen, die eine Autoimmunantwort 
favorisieren – wie z.B. die Bystander-Aktivierung, die Anwesenheit myelin-reaktiver T-
Zellen, die Depletion regulatorischen T-Zellen oder Applikation demyelinisierender 
Antikörper – führen in Kombination mit induziertem ODZ-Untergang nicht zur 
Entwicklung einer gegen das ZNS gerichtetet Autoimmunität. Wir konnten folglich 
zeigen, dass diffuser ODZ Tod alleine oder in Verbindung mit einer Aktivierung des 
Immunsystems sehr wahrscheinlich kein Auslöser einer persistierenden ZNS-
Autoimmunität ist.  
Zum Zweiten haben wir die Bedeutung Insulin-ähnlicher Wachstumsfaktoren (IGF1R) 
in autoimmunen und toxischen Demyelinations modellen der Maus untersucht. 
Überlebende ODZ, die MS Läsionen im ZNS umgeben, regulieren IGF1R und Insulin-
ähnliche Wachstumsfaktoren 1 (IGF-1) hoch, was auf einen Einfluss dieser Zytokine 
auf die Formation entzündlicher Demyelinisierungsherde hinweist. Frühere Studien 
konnten ausserdem zeigen, dass IGF-1 ein anti-apoptotischer, myelinogener Stimulus 
für ODZ sein kann. Mit Hilfe eines zweiten Mausmodells (oIGF1R) konnten wir IGF1R 
selektiv in reifen ODZ ausschalten. Dies führte zu verbesserten klinischen Symptomen 
nach Induktion einer gegen das Myelin-gerichteten Immunreaktion und entzündlichen 
ODZ Schädigung (ExperimentelleAutoimmune Enzephalomyelitis, EAE). Im 
Gegensatz hierzu führte der toxische ODZ Tode nach Gabe von Cuprizone zu erhöhter 
ODZ Sterblichkeit und verringerter Remyelinisierung in Abwesenheit des IGF1R. Diese 
Ergebnisse weisen auf eine unterschiedliche Rolle des IGFR1 in Abhängigkeit von der 
Art des OLZ Schadens (inflammatorisch versus toxisch) hin  
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Zum Dritten haben wir ein Mausmodell generiert (oLucR), um die Dynamik der 
Demyelinisierung und Remyelinisierung in vivo und Echtzeit bildlich darzustellen 
Hierzu haben wir das Reportergen Luciferase nach Cre-vermittelter Rekombination in 
reifen ODZ unter der Kontrolle des β-Actin Promoters exprimiert. Im oLucR Modell 
konnten wir reproduzierbar eine Zunahme der in vivo Biolumineszenz messen, die mit 
dem Beginnder Neuroinflammation und Demyelinisierung im ZNS zeitlich korrelierte. 
Dieses deutet darauf hin, dass ODZs unter demyelinisierenden Bedingungen einen 
“aktiven Phänotyp“ annehmen können, welcher sich durch eine gesteigerte 
Zytoskelettmotilität auszeichnet. 
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INTRODUCTION 
 
 
Glia  
 
In virtually every animal species, the nervous system comprises neurons and glial cells. 
The latter have continuously grown in number along the course of evolution of complex 
nervous systems, and in the primate order glia strongly outnumber neurons constituting 
90% of the cells of the central nervous system (CNS) [1]. Glial cells were first 
discovered by the groundbreaking work of Virchow, who was able to discern these new 
cells from neurons defining them “nerve glue”. Subsequently, especially thanks to the 
contributions of Ramon y Cajal and Rio Hortega, three cell types were distinguished 
dividing neuroglia into astrocytes, microglia, and oligodendrocytes (ODCs) (Fig. 1). 
Since then, a reductive vision of these cells as mere “holding glue” of the CNS has 
stigmatized their biological importance compared to the “effectory” components of the 
CNS, the neuronal cells. However, this misleading simplification has been outdated in 
recent times thanks to a growing number of evidences pointing at glial cells for 
countless vital functions in supporting neurons and, most importantly, finally stressing 
their role in human diseases.  
 
Astrocytes and microglia 
 
Astrocytes are highly heterogeneous glial cell type. They are usually divided into two 
groups: protoplasmic, found in the CNS gray matter and directly controlling blood 
vessels and synapses, and fibrillary, mainly found in the CNS white matter and 
contacting nodes of Ranvier besides blood vessels. Astrocytes extend a fine network of 
thousands of membranous processes that contact directly vessels and synapses (Fig. 2, 
left). Also, they are highly reactive upon stimulation and astrocyte activation is a result 
of virtually any perturbation of the CNS, implying both morphological changes and 
increased release of signaling mediators. Altogether, this reactive condition is defined as 
gliosis. Beyond this role in response to injuries, astroglia exert many other fundamental 
steady-state functions as the metabolic coupling of synaptic activities, the reuptake of 
neurotransmitters and ions (mainly K+) from synapses and nodes of Ranvier, and 
participation in the formation of the blood brain barrier (BBB). The BBB (or 
neurovascular unit) is a functional feature of the CNS vasculature in which reduced 
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rates of endocytosis, diffuse tight junctions among endothelial cells, high membrane 
levels of active transporters and astrocytic end-feet create a biological separation 
between the CNS and the periphery (see Immune-privilege in the CNS section). It has 
been proven that astrocytes directly affect the formation and the number of neuronal 
synapses in vitro and in vivo controlling pre- and post-synaptic functions through the 
release of mediators such as thrombospondin and D-serine. These functions are 
influenced by neuronal ATP and neurotransmitter levels which produce intracellular 
Ca2+ waves in astrocytes and thus couple local neuronal activity to astrocytic support of 
synaptic formation. Also, similar mechanisms seem to govern synaptic plasticity 
following different pathological conditions [2, 3]. This functional coupling between 
astrocytes and neurons is also evident in the BBB, in which neurons can directly affect 
astrocytes controlling neurovascular permeability through effects on vasodilatation and 
vasoconstriction. Astrocytes are connected to the non-compacted myelin of ODCs 
through gap junctions, and thus possibly provide ODCs and internodes (see next 
section)  with indirect access to blood metabolites. Along this line, it has been proven 
that impairment in astrocytic function directly affects ODC survival, as shown in glial 
fibrillary astrocytic protein (GFAP)-null mice and in human patients suffering from 
Alexander disease [4, 5]. Finally, astrocytes are also known as important providers of 
growth factors for neurons (alike ODCs, which produce factors as NGF, BDNF, NT-3 
and Insulin Growth Factor 1, IGF-1 – reviewed in [6]).  
The other major glial cell type in the CNS is microglia, which constitute about the 15% 
of the cells of the adult CNS and the only member of the immune system in the CNS 
parenchyma. Microglia originate from uncommitted myeloid progenitors derived from 
the Yolk sac and invading the CNS before embryonic day 9 [7]. As astrocytes, 
microglia are highly sensitive and display numerous membranous symmetrical 
extensions which are highly motile and sample the extracellular space with high 
turnover in a seemingly random fashion (Fig. 2, right). As cells of the immune system, 
microglia possess phagocytic capabilities and can act as antigen presenting cells (APCs) 
through antigen internalization and presentation in the context of Major 
histocompatibility complex-I (MHC-I) and MHC-II molecules (see The immune system 
section). Hence, one of the main functions of microglia appears to be the 
communication of parenchymal distress towards the peripheral immune system through 
the aforementioned antigen presentation and through release of inflammatory cytokines 
as TNFα. Also, it seems that microglia play a developmental role in the formation of 
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neural circuits through the engulfment of inappropriate synaptic connections targeted by 
the complement factor C1q [8].  
Importantly, microglia are homogenously distributed in the adult CNS and thus able to 
constantly screen the entire brain parenchyma [9]. However, this constant surveillance 
of their microenvironment is generally not reflected by classic activation markers of the 
monocyte lineage. In fact, microglia display few phagocytic markers and very low 
levels of membrane ligands and opsonic receptors which are usually associated to 
activated macrophages as FcγRs, CD11b/CD18 (also known as complement receptor 
type 3), mannose receptor and CD14, the receptor mediating the effects of LPS [10]. 
Different kinds of stimuli and danger signals result in strong upregulation of these 
markers along with morphological changes which render microglia more similar to 
effector cells of the macrophage lineage. In their constant surveillance, microglia appear 
to be strongly influenced by the local neurochemical environment, in a complex 
interplay between pro-activation factors as ATP and suppressing mediators as 
neuron/glial-produced neurotrophins (also show to contrast activatory effects of IFNγ 
and LPS). In this delicate balance, microglia response is continuously shaped and 
downregulated by direct cell-to-cell neuronal signaling including members of the so-
called “neuroimmune regulatory proteins” as OX2A, CD47, CD200, and fractalkine 
(CX3CL1). Signaling through these membrane-bound molecules represent thus a tonic 
signal which limits microglial activation in the healthy CNS, protecting parenchymal 
cells from the possibly detrimental effects of sustained immune activation. Nonetheless, 
activated microglia seem to play a major role in CNS inflammation both as producers of 
pro-inflammatory cytokines and immune regulatory molecules (IL6, IL1, TNFα, IL12, 
IL18), and as producers of anti-inflammatory components (Il10, IL1Ra, TGFβ). The 
control mechanisms behind these opposite function are still unclear, with mediators as 
IFNγ, IL4 and prostaglandins shown to play a major role [10]. Altogether, and similarly 
to astrocytes, the exact range of microglial functions is still unknown and both their 
hypothetical harmful and protective role in different CNS pathologies remain hotly 
debated.  
 
Oligodendrocytes and myelin 
 
ODCs are the myelinating cells of the CNS. These cells exist in different loosely-
characterized subtypes which vary according to different studies [11-13] and have their 
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peripheral counterpart in Schwann cells, which evolved in parallel to CNS ODCs and 
myelinate peripheral nerve fibers. Myelin is a multi-layered, lipid-enriched biological 
membrane which is wrapped around neuronal axons thus allowing faster signal 
conduction (Fig. 3). Little is known about the effective resistance of this insulating 
membrane, but its average properties seem to vary between CNS regions and possibly 
between ODC subtypes [14]. While simpler nervous systems generally display mere 
glial engulfment of axons with clustering of ion channels, myelin is a specialized 
accomplishment of late animal evolution [15]. Myelin is produced by ODCs in their last 
developmental stage (see next section) and insulates up to 50 neuronal axons, thus 
creating an extensive and complex network between ODCs and surrounding neuronal 
cells. Myelination is a tightly regulated process in that ODCs envelops 
contemporaneously all their target axons in a sharp time frame of 10-18 hours [16]. It 
was calculated that during this active phase of myelination every ODC produces almost 
5000 µm2 of myelin surface per day, and a final total myelin surface of 1-20 x 105 µm2. 
Naturally, this is reflected by high metabolic demands and high plasticity of the ODC 
cytoarchitecture (actin filaments and microtubules). In the main white matter regions of 
the CNS, ODCs myelinate only axons with a diameter larger than 0.2 µm [17], while in 
other regions as cortex and optic nerve also smaller axons can be enwrapped. Larger 
axons are the first to recruit glial progenitors and receive more layers of myelin when 
compared to small diameter axons. Nonetheless, the ratio between inner axonal and 
fiber diameter, called g-ratio, remain constant among all CNS axons. Also, several 
studies have shown that the presence of a myelin sheath increases the axonal diameter 
promoting local accumulation and phosphorylation of neurofilament (NF) subunits [18].  
On the same axons, adjacent myelin sheaths always belong to different ODCs and mark 
the borders of small unsheathed regions known as nodes of Ranvier, in which clustered 
voltage-gated Na+ channels allow saltatory impulse conductance along the axon. The 
flanking paranodal axo-glial junction creates an almost impermeable diffusion barrier 
and is organized by a complex set of adhesion and scaffolding proteins. The myelinated 
region lying between nodes of Ranvier -hence called internode- is divided into 
structurally different and functionally specialized domains. During myelination, 
overlaying contiguous myelin membranes extrude their cytoplasm and become strongly 
interconnected to form “compact myelin”, mostly responsible for fast neuronal 
signaling. At the same time, the surrounding myelin is organized in looser loops 
representing a direct continuation of the ODC cytosol, with a complex system of 
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microtubules sustaining this metabolically active part of the membrane hosting 
numerous ion transport channels and enzymatic activities. The underlying 
cytoarchitecture is incredibly complex, with actin filaments mostly associated to 2’-3’-
cyclic nucleotide 3’-phosphohydrolase (CNP-1), a typical ODC marker. Compared to 
microtubules, which are distributed throughout the cells body and in large myelin 
processes, actin filaments play a main role during OPC migration, axon targeting and 
subsequently in thinner membrane domains of the myelin sheath [19].   
As reported above, the dry weight of myelin (which has only 40% of water content) is 
mainly composed of lipids which comprise 32% glycolipids, 26% cholesterol and 42% 
phospholipids; together, these components account for the physical insulation properties 
of the membrane. Compared to other biological membranes, myelin is relatively poor in 
proteins (30% of dry weight), which however comprises countless protein types, the 
most abundant being proteolipid protein (PLP) and its alternative spliced isoform DM20 
(50% of total protein content), myelin basic protein (MBP), myelin associated 
glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), and CNP. Every 
myelin protein is specific in function and in the localization between compact or non-
compact myelin, with some appearing to be strictly necessary for correct myelination 
and ODC survival. Among these, mutations in PLP, a cholesterol-binding protein 
responsible for compaction and stabilization of the membranes, and in MBP, also 
implied in stabilization of compact myelin, have been shown to result in severe CNS 
hypomyelination and ODC cell death (see Oligodendrocyte support of axonal integrity 
section). 
 
Oligodendrocyte origin and differentiation 
 
The origin and differentiation of ODCs have been thoroughly investigated (Fig. 4). 
These cells originate as multipotent neuroectodermal Nestin+ precursors of the 
subventricular zone, which mature into postmitotic myelinating cells while migrating to 
their final destination. ODCs populating the spinal cord originate in two waves: the first 
from the ventral ventricular zone, which give rise to ODC precursors cells (OPCs)  
migrating dorsally through the entire spinal cord; the second wave originates from the 
dorsal spinal cord, and makes up for at least 10% of the ODCs in the spinal cord. In the 
brain, OPCs initially originate in the medial ganglionic eminence and in the anterior 
entopeduncular area of the ventral forebrain. Then, a subsequent wave from the caudal 
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and lateral ganglionic eminences and a final wave within the postnatal cortex complete 
the OPC population. These developmental waves of cells appear to be functionally 
redundant, as depletion of one population is compensated in vivo by subsequent waves 
of OPCs. Nevertheless, different waves compete with each other in populating CNS 
regions in a process regulated by limited amounts of growth factors (as platelet-derived 
growth factor, PDGF) [20]. For instance, cells from the first wave of forebrain OPCs, 
possibly an evolutionary relic, are eventually lost from the adult pool.  
Newly-produced OPCs must travel long distances to get to their final destination, and 
this complex migration is aided by direct contact with extracellular matrix components, 
axons and astrocytes, and soluble factors such as growth factors (among these, PDGF, 
fibroblast growth factor; FGF, hepatocyte growth factor; HGF), chemotropic proteins 
(netrins and semaphorins) and chemokines (i.e. CXCL1) [21]. OPC differentiation 
comprises different stages defined by sequential expression of developmental markers 
and changes in proliferative capacity, migratory ability, and morphology. The earliest 
marker specific for the ODC lineage during the neuroectodermal progenitor stage is 
Olig2, as shown by Olig2-deficient mice which lack completely ODCs. OPCs are kept 
in an undifferentiated proliferating stage by the steady-state expression of inhibitory 
factors as Id2, Id4, Hes5, and Sox6. It was shown that the decrease of extracellular 
inhibitory signals allows the downregulation of these factors and in turns the 
derepression of the pro-differentiation transcription factors Nkx2.2, Sox10, YY1, Olig1, 
and TCf4. These players form a complex with the newly-expressed myelin gene 
regulatory factor (MRF) and lead to a postmitotic myelinating stage. At the same time, 
intrinsic differentiation control is exerted by chromatin remodeling mechanisms (such 
as histone deacetylases-driven inhibition of the Wnt/β-catenin pathway) and by 
microRNAs, with molecules such as miR-219 and miR-338 shown to play pivotal role 
in the downregulation of the anti-differentiation factors PDGFR, Sox6, and Hes5.  
Together with Olig2, Olig1, and PDGFR, the progenitor stage is also characterized by 
expression of the sulfate proteoglycan NG2 and precedes a stage defined by expression 
of glycolipids identified by the O4 antibody. In the latter, ODC behaviour changes 
drastically as loss of cell motility and decrease of the PDGFR-related mitogenic 
response are observed [22]. Eventually, OPCs maturate into pre-oligodendrocyte and 
start expressing RIP and the first myelin proteins in CNP-1, GalC, MBP, MAG and 
PLP. It has been shown that within single ODC processes, the switch from the 
expression of the early isoform DM-20 to PLP indicates the actual beginning of 
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myelination [23], with MOG being the last major myelin protein to be expressed [24].  
Altogether, the exact timing of myelination is controlled by an intrinsic molecular clock 
and by external factors such as secreted molecules, axonal surface ligands, and axonal 
activity. ODC myelination seems to be fairly independent in vivo from the activating 
NRG1/ErbB signaling, which is instead necessary for the myelination process in 
peripheral Schwann cells [25]. Most of the axonal ligands discovered so far are actually 
inhibitory, acting to suppress myelination or to actively maintain an undifferentiated 
state in OPCs. These axonal factors include Jagged, PSA-NCAM, and LINGO-1. An 
important role in this context is also played by the aforementioned Wnt/β-catenin 
pathway, which is transiently active in between differentiation from OPCs to mature 
ODCs. However, while axonal signaling accounts for every step in the differentiation 
and maturation of Schwann cells in the PNS [26], neurons and neuronal activity seem to 
be surprisingly dispensable for correct in vitro OPC differentiation and myelination, 
again highlighting the existence of an intrinsic cellular clock. Even so, it was observed 
that most OPCs express the ionotrophic glutamate receptor as well as voltage gated-ion 
channels and respond to glutamate input with miniature post-synaptic excitatory 
potentials. An elegant hypothesis has thus been put forward postulating that firing naked 
axons could directly influence nearby OPCs and stimulate their differentiation in 
myelinating ODCs. Also, adenosine released by neural activity seems to have a direct 
effect in inhibiting OPC proliferation and enhancing differentiation [27], while axonal 
electric activity has a primary role in the localization of PLP proteins to the myelin 
membrane by exocytosis [28]. At the same time, astrocytes were proven to be indirectly 
involved in connecting neural activity to OPC differentiation through their release of 
leukemia inhibitory factor, an enhancer of ODC myelination, in response to ATP 
released from nearby firing neurons [29].  
 
Oligodendrocyte susceptibility to damage  
 
ODCs are highly susceptible to oxidative damage. Indeed, the main reason for this 
sensitivity is the metabolically-demanding maintenance of the myelin membrane, which 
constitutes approximately 100 times the cell body weight [30]; accordingly, actively 
myelinating ODCs are even more sensitive. Myelination requires an enormous amount 
of both oxygen and ATP which can lead to toxic byproducts such as reactive oxygen 
species, and an intense protein production which increases the risks of protein 
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misfolding within the endoplasmic reticulum [31] [32]. Furthermore, ODCs show an 
intrinsic high production of hydrogen peroxide in peroxisomes and constitute the largest 
sink for iron in the CNS [33], as many myelin-related enzymes require iron as a co-
factor. Thus, these aspects and the low concentrations of intracellular anti-oxidative 
agents (i.e. glutathione) strongly increase the risk of intracellular free radicals, 
especially under harmful conditions [34].  
Oxidative damage in ODCs is known to activate the sphingomyelinase/ceramide 
pathway, which can be also triggered during injury, infections or inflammation [35]. In 
these conditions, activated sphingomyelinase enzymatically releases ceramide from 
sphingolipids within ODCs, thus leading to apoptosis.  
Also, cells of the ODC lineage are susceptible to excitotoxic death in that they express 
NMDA, AMPA, kainate and ATP (P2X7) receptors, and can thus be damaged by high 
levels of extracellular glutamate or ATP [36] [37] [38]. Furthermore, ODC-specific 
NMDA and AMPA receptors show structural differences and lack many control 
features compared to their counterparts in other cells, and can thus be dangerously 
activated at low potentials [39]. However, with the important exception of the NMDA 
receptor -possibly playing a role in the neuron/ODC unit-, these receptors are solely 
express in OPCs and are heavily downregulated after maturation [32]. 
ODCs can also be damaged by activated astrocytes, reactive macrophages and 
inflammatory cells (see Oligodendrocytes and immunity in the sclerotic CNS section). 
For instance, ODC degeneration can be caused by inflammatory mediators produced by 
reactive microglia/astroglia such as oxygen and nitric oxide-radicals (affecting 
mitochondrial respiration), glutamate, TNFα, and IFNγ [40] [41]. These molecules play 
important roles in bystander ODC death and demyelination during virtually any CNS 
disease as ischemic stroke, traumatic injury, radiation necrosis, leukodystrophies and 
MS, although in the latter case additional adaptive immune destructive mechanisms do 
take place.  
 
Oligodendrocyte support of axonal integrity  
 
More than mere myelinating cells, ODCs have been proven fundamental also for 
functional integrity and long term survival of axons.  This aspect has been investigated 
in different transgenic animal strains and is important in the understanding of human 
diseases such as MS (see Multiple sclerosis section) and inherited leukodystrophies of 
the CNS. In these pathologies, prolonged demyelination is associated with neuronal 
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death and thus contributes to the accumulation of clinical disabilities [42]. 
Leukodystrophies arise in patients carrying a mutated ODC-related gene and include 
different pathologies such as Pelizaes-Merzbacher disease (PMD, PLP-1 mutations, 
myelin gene), PMD-like disease (GJC2 mutations, gap junction protein), Canavan 
disease (ASPA mutations, aspartoacylase enzyme), X-linked adrenoleukodystrophy 
(ABCD1 mutations, peroxisome gene), and metachromatic leukodystrophy 
(Arylsulfatase A mutations, myelin enzyme). 
The characteristic ODC dysfunctions in these pathologies lead to myelin degeneration 
which deprives axons both of electrical insulation and of a physical barrier isolating 
them from the CNS environment. Therefore, naked axons become extremely vulnerable 
to matrix metalloproteinases (MMPs) produced by inflammatory infiltrates and to the 
diffusion of nitric oxide (NO) produced by activated microglia, which leads to a 
perturbation in mitochondrial ATP generation [43]. Mere demyelination can lead to 
neuronal distress even in the absence of inflammatory components: the absence of 
insulation itself leads to a drastic redistribution of axonal voltage-gated Na+ channels, 
thus resulting into higher energy consumption. In this scenario, an energetic threshold 
can be reached in which Na+/Ca2+ exchangers would reverse direction of ionic flow, 
thus filling the axon with Ca2+ ions and leading to mitochondrial impairment followed 
by Wallerian-like axonal degeneration. This may trigger a vicious circle in which 
sudden glutamate release from degenerating axons leads to glutamate excitotoxicity in 
ODCs and additional neurons.  
However, some transgenic mice show that myelin absence per se does not necessarily 
lead to neuronal death. In the shiverer mouse strain, resulting from a major deletion in 
the MBP gene, axons are generally enwrapped by few non-compacted myelin layers and 
many large-caliber axons remain virtually unmyelinated. However, in this mouse model 
normal ODC survival and no neuronal loss were described, even in the presence of 
higher mitochondrial numbers in the unsheathed axons [44]. Evidently, axonal survival 
can be maintained by surviving ODCs without the support of properly formed myelin. 
Interestingly, it has been observed that some minor myelin abnormalities which do not 
lead to demyelination can actually cause neuronal impairment and death. In the PLP-1 
null mouse, electrical conductance is normal and minor myelin alterations are solely 
detectable by ultrastructural analysis. However, after few months these mice show 
reduced axonal transport and subsequent neuronal degeneration in the presence of a 
physically stable myelin. Mice carrying a mutation in the CNP-1 gene show a similar 
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albeit faster clinical pathology: after exhibiting an apparently normal developmental 
myelination, a degeneration in the paranodal junctions leads to axonal defects and 
neuronal death. Evidently, axonal impairment does not solely rely on the missing 
insulation properties of myelin but most likely on unclear fine changes in cell-to-cell 
signaling.  
In this respect, the complete scenario of interactions and mutual communications 
between ODCs and neurons is far from being understood. 99% of the axonal surface are 
covered by internodes which deprive the neuronal surface of free exchange of 
metabolites; consequently, ODCs must be the main players in defining the extracellular 
milieu suitable to the axon. It has also been postulated that active diffusion of 
metabolites and specific transporters would play a role in this cellular interplay. From 
this perspective, ODC dysfunctions could account for neuronal impairment also in 
classic neurodegenerative disease (i.e. Alzheimer), and as such should be investigated in 
human patients and animal models [42]. 
 
The immune system 
The immune system is composed by many interdependent cell types that protect the 
body from external pathogens and from the growth of tumor cells. Every cell in the 
system shows different highly-specialized functions such as bacteria engulfment, killing 
of parasites, depletion of infected and degenerated cells, and fine functional regulation 
of other cell types. The immune system can be broadly divided into two effector arms: 
an innate arm, which include cells able to immediately respond to harmful elements 
through the recognition of common pathogenic molecules, and an adaptive arm, 
including cells (such as lymphocytes) which are highly specific towards a particular 
antigen and able to confer long-lasting protection to the host through the development 
of an immunological memory. Regardless of their functions, all cells of the immune 
system derive from bone marrow stem cells in a process called hematopoiesis (Fig. 5). 
In this, while most cells (for instance B cells) mature directly within this organ, others 
(i.e. T cells) migrate elsewhere to maturate further. In the thymus, T cell precursors 
undergo a complex multistep maturation while being tested for correct expression 
(positive selection) and specificity (negative selection) of their T cell receptor (TCR) 
(Fig. 6). Antigen specificity, and activation of T cells, relies on specific TCR 
recognition of a target antigen presented in the context of MHC-I (for CD8+ cytotoxic T 
cells) and MHC-II (for helper CD4+ T cells) molecules (Fig. 7). In this fine selection 
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process, dangerous T cells which are able to recognize self antigens with high affinity 
and hence to trigger autoimmune inflammation are forced to undergo apoptosis and thus 
removed from the effector pool. While in primary immune organs such as thymus and 
bone marrow this selection process is mediated by local specialized parenchymal APCs, 
naïve and mature circulating lymphocytes are able to recognize their cognate antigens 
only when presented by professional APCs as B cells, macrophages, and dendritic cells.  
Immune-privilege in the CNS 
The importance of the immune system is evident in immunodeficiency disorders, 
pathologies characterized by the absence of certain cellular components or by defective 
functioning of immune cells and inflammatory cascades. Nonetheless, along animal 
evolution certain organs have developed a striking resistance to the development of 
inflammation, a quality called “immune privilege”. The concept of an immune privilege 
of the CNS dates back almost one century to the first experiments of tumor grafting 
from the rat to the mouse brain: while the transfer of foreign tissues would result into 
immediate local inflammation and graft rejection in most organs, the mouse brain 
showed a surprising lack of inflammation. The absence of an immune-mediated 
rejection showed that the CNS was somehow disconnected from the peripheral immune 
system, a finding confirmed through several additional experiments of tissue grafting 
and viruses, vectors, and bacteria administration. In parallel, the concept of a BBB 
protecting the CNS grew strong and the two findings reinforced each other resulting 
into a scientific paradigm that has been only recently revised and redefined [45]. From 
an evolutionary perspective, the immune privilege represents an adaptive advantage in 
protecting delicate and essential organs from the detrimental consequences of acute and 
chronic inflammation. As such, it is extended to testicles, eyes, and placenta. The 
immune privilege of the CNS is actually limited to the sole parenchyma: 
intraventricular or meningeal administration of pathogens or tumors trigger a normal 
and sustained adaptive immune response. In fact, these extra-parenchymal CNS areas 
are constantly surveyed by APCs: macrophages and dendritic cells are present both in 
choroid plexus and meninges, and perivascular macrophages surround small and 
medium-size blood vessels displaying phagocytic and immune regulatory functions 
[10]. On the contrary, the uninflamed parenchyma seems to be devoid of APCs (in 
particular dendritic cells) able to bear antigens from an immune-challenged CNS to 
peripheral immune organs such as lymph nodes (LNs) and spleen; even during CNS 
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inflammation, no evidence of APCs migrating to peripheral organs could be found. 
Antigen-specific lymphocyte activation might thus happen in situ, as shown by the 
formation of follicle-like structure in the less-immune-privileged meninges. 
Nonetheless, even though devoid of cellular routes of antigen drainage, the CNS 
constantly allows the passage of soluble antigens to the periphery. Interstitial 
parenchymal antigens can reach the cerebrospinal fluid (CSF) along the artery walls, 
and from there the spleen through the arachnoid villi and the venous sinuses; 
furthermore, a continuous albeit limited lymphatic flow reaches the deep cervical (dp) 
lymph nodes from the brain area and the lumbar lymph nodes from the spinal cord [46].  
Several other mechanisms exist to avoid sustained inflammatory damage to the CNS. 
The main barrier towards the establishment of immune reactions within the CNS is the 
expression level of MHC-I and MHC-II molecules: at steady state, all cells express very 
low levels of MHC-I and virtually no CNS cell express MHC-II molecules. Astrocytes 
actively suppress the effector functions of activated T cells through cytokine signaling 
and are able to induce direct apoptosis through FasL-Fas interaction (as neurons do), 
while microglia express co-stimulatory molecules as B7-H1 which negatively impact T 
cell activation. Also, an elegant study by Liu et al. [47] has recently shown that neurons 
possess the faculty to skew activated T cells into suppressive regulatory T cells (Tregs) 
in a TGFβ-dependent manner. Lastly, the already described BBB limits the entry of 
solutes and ions and allows a tight control over cell migration. Altogether, the CNS 
possess a strongly anti-inflammatory environment which limits the detrimental effects 
of immune reactions while decreasing drastically the potential benefits of 
neuroinflammation in pathogen clearance and repair (Fig. 8). The reasons for this 
compromise are clear: once immune cells are effectively primed towards CNS antigens, 
the immune privilege is lost and inflammation sets in along with sustained tissue 
destruction. This scenario is best reflected in the CNS of MS patients. 
Multiple Sclerosis 
 
MS is a chronic inflammatory and demyelinating disease of the CNS with largely 
unknown etiology and no effective cure. The symptoms of the disease are diverse, but 
include tremor, fatigue, and paralysis [48]. The first description of MS dates back to 
1868 with clinical observations by Jean-Martin Charcot. Nowadays, MS represents the 
most common neurological disorder in young adults in particular in northern Europe, 
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North America and southern Australia, affecting more than two million people 
worldwide with a prevalence ranging between 2 and 150 : 100.000 [49]. Disease 
initiation is commonly associated with early adulthood and is more common in females, 
with a 2 to 1 female/male ratio among patients [48]. Under the definition of MS lie a 
series of clinically heterogeneous pathologies which can broadly be divided into a more 
common relapsing-remitting (RR) form (80% of patients), characterized by episodic 
disease progression, and a primary progressive form, with disabilities slowly 
accumulating over time. Often, the RR form develops into a secondary-progressive 
stage characterized by absence of remitting phases.  
Histopathologically, MS presents with large, multifocal demyelinated lesions scattered 
throughout the CNS. These lesions are known as sclerotic plaques [50]. They are 
usually detected by gadolinium-enhanced T1-weighted or T2-weighted MRI analysis, 
which are the most common non-invasive diagnostic tools for MS (Fig. 9). In affected 
areas ODC death and axonal degradation, gliosis, and activation of microglia are 
observed [51, 52] and perivascular and parenchymal accumulation of T cells, B cells 
and macrophages [53] are found (Fig. 9). Such inflammatory infiltrates are thought to 
reflect an immune response against the CNS, especially myelin antigens, resulting in the 
disruption of the myelin sheath. Oligoclonal bands in chromatograms of cerebrospinal 
fluid from patients indicate antibody production within the CNS, possibly targeted 
towards myelin antigens [54]. Genetic linkage analysis identified several genetic 
regions belonging to the immune system with HLA-DR loci as major and IL2RA and 
IL7R loci as minor risk factors for MS [55-57]. At the same time, increased 
susceptibility was also associated to CNS-specific genes as GalC and a neuronal kinesin 
[58]. In summary, these observations suggest that MS is an autoimmune disease 
targeting an hypothetically inflammation-prone CNS. The targets of this detrimental 
adaptive response seem to be CNS antigens which are normally segregated from the 
peripheral immune system within the immune-privileged parenchyma. Myelin-reactive 
T cells are found in blood, CSF and brain tissue of patients. It is believed that these 
autoreactive lymphocytes evade the thymic negative selection process thanks to weakly-
binding self-reactive TCRs. As possible activating mechanisms, molecular mimicry and 
bystander activation upon infection have been suggested [59]. In the latter scenario, 
pathogen-triggered chronic activation of lymphocytes and APCs would result into 
upregulation of co-stimulatory molecules, release of inflammatory mediators, and in 
turn to random bystander activation of self-reactive T cells. The concept of molecular 
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mimicry is based on the promiscuity of TCR specificity. Pathogenic components of 
virus and bacteria “mimicking” self peptides could thus activate autoreactive T cells as 
has been shown in vitro for several MBP-reactive T cell clones. The list of common 
pathogens candidates for disease initiation includes Epstein Barr virus, herpes simplex 
virus, and Chlamydia pneumonia [60], although up to now none of these could be 
causally linked with the pathoetiology of MS. Despite the activation trigger is still 
unclear, the mechanism of T cell invasion in the CNS parenchyma has been intensively 
studied. Different lymphocyte adhesion molecules have been implicated in MS and 
among these very late antigen 4 (VLA4) and lymphocyte-function associated antigen 
(LFA-1) with their binding partners VCAM1 and ICAM1 on the vascular system. These 
molecules are highly upregulated on the blood vessels of MS patients and are held 
responsible for the perivascular accumulation of lymphocytes. Accordingly, one of the 
most effective drugs in MS therapy, natalizumab, binds to VLA-4 thus inhibiting T cells 
invasion and resulting in a good amelioration of clinical conditions [61]. After 
perivascular accumulation, extravasation of inflammatory cells to the CNS through a 
disrupted BBB is aided by release of MMPs and by unbalances in the regulatory 
elements called “tissue inhibitors of MMPs” (TIMPs). MMPs are produced by a variety 
of cell types including monocytes, macrophages, endothelial cells and are used in the 
healthy CNS by parenchymal glial cells for plasticity and repair [61].  
Following accumulation and CNS invasion, activated T cells and blood-derived 
macrophages can cause ODC damage through different mechanisms. 
 
Oligodendrocytes and immunity in the sclerotic CNS   
 
Evidence that ODCs are heavily depleted within sclerotic lesions dates back to the first 
comprehensive literature regarding MS; since then, ODC absence and demyelination are 
considered hallmark features of the disease [62]. Whether demyelination can be 
uncoupled from cell death is however still unclear. Several reports indicate ODC 
survival within heavily-demyelinated sclerotic lesions, often in close proximity to  
myelin-containing macrophages [62]. A dutch study of post-mortem CNS tissues went 
further in showing that demyelinated adult MOG+ cells could survive in situ after 
immune attack [63]. Other reports indicate the existence of phenotypically 
“hyperplastic” ODCs which are engulfed by reactive astroglia in a process called 
“emperipolesis”, possibly representing a peculiar protective mechanism [62]. 
Nevertheless, the majority of ODCs within sclerotic plaques die. In this, different 
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mechanisms and cellular mediators could account for the destructive process and 
include macrophages and microglia, astrocytes, and different lymphocyte subsets 
among which γδ T cells, CD4+ T cells, CD8+ T cells, and B cells (Fig. 10).  
The first demonstration of a humoral component in the pathology of MS dates back to 
1964 [64], when it was shown that MS sera were capable of triggering demyelination in 
organotypic CNS slice cultures through the induction of ODC lysis in a IgG dependent-
manner [62]. Also recent histopathological investigations seem to indicate antibody-
mediated demyelination as a common pathogenic mechanism in chronic MS, as shown 
by the high and consistent presence of Fcγ+ phagocytic macrophages within 
demyelinating plaques. At the same time, diffuse presence of complement and antibody 
suggests that antibody- and complement-mediated demyelination play an important role 
[65]. Thus, B cell activation seems to be a destructive hallmark of the disease. As for T 
cells, many different subtypes seem to play a role in a complicated interplay which is 
still somewhat elusive. For instance, γδ T cells have been implicated in perforin-
dependent lysis of ODCs in vitro and in vivo within MS lesions. Clonal expansion of 
cytotoxic CD8+ T cells was demonstrated in lesions, blood and CSF, and ODCs are 
shown to express MHC-I in animal model of CNS inflammation and in MS. On the 
contrary, MHC-II expression by ODCs, -controversially reported in some in vitro ODC 
cultures [66]- has never been proven in vivo [67]. Nonetheless, CD4+ T helper 1 cells 
can activate surrounding APCs to release pro-inflammatory mediators and thus 
indirectly harm ODCs. A possible reason for the sustained activation of pro-
inflammatory T cells can be found in impairment in Tregs, which displayed a lower in 
vitro ability to suppress activated T cells when isolated from MS patients [61]. In this 
delicate balance among lymphocyte subsets, CD4+ T helper 2 cells can have beneficial 
effects through the release of anti-inflammatory mediators as IL4, IL10, and IL13 (Fig. 
8). Accordingly, different drugs used in MS clinical testing (as glatimer acetate) have 
proven that clinical amelioration and reduction of relapses in patients is associated with 
skewing of the immune balance towards T helper 2 cells instead of T helper 1 cells.  
As already mentioned, also microglia can participate in tissue destruction and 
demyelination. For instance, ODCs in MS lesions overexpress the death receptors for 
TNFα, TNFβ (Lymphotoxin, LT), and Fas, while reactive microglia in proximity 
express high levels of FasL, LTs, and TNFα. Although this overexpression of death 
mediators is considered a mechanism to deplete Fas-expressing lymphocytes in the 
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inflamed CNS (apoptotic lymphocytes have in fact been reported several time in MS), 
this could also clearly result in ODC death [44]. Furthermore, activated by lymphocytes 
in situ, microglia (and astrocytes) can trigger demyelination also through the release of 
reactive oxygen and nitrate species within MS lesions. Lastly, astrocytes can indirectly 
harm ODCs through an unbalanced glutamate reuptake from synapses which can result 
into ODC excitotoxic death. Altogether, countless demyelinating mechanisms exist 
within the inflamed CNS.  
However, ODCs are not only passive targets of tissue destruction. In the presence of 
inflammatory mediators and within ischemic/hypoxic environments, ODCs have been 
shown to upregulate factors of hypoxic preconditioning as HIF1α, HSP70 and HSP32, 
thus showing the activation of intrinsic protective mechanisms in response to 
inflammation. Also, ODCs can express several growth factors as IGF-1, NGF and 
TGFβ, all shown to be protective in different models of MS. Interestingly, ODCs in the 
context of the normal-appearing white matter (NAWM) of MS patients upregulate 
components of the STAT6 pathway as STAT6, JAK1, IL4R, and IL13R, better known 
for their necessary function in the anti-inflammatory T helper 2 subset, and chemokines 
as CXCL10, CCL2, and CCL5 after stimulation with IFNγ [67]. Altogether, it seems 
that ODCs are able to condition the surrounding environment and can possibly act as 
immunomodulators. Thus, these cells can play a role in limiting inflammatory responses 
and damage.   
         
Is MS a primary neurodegenerative disease? 
 
In the last decade, histopathological analyses have suggested that neurodegenerative 
mechanisms independent of inflammation are responsible for some aspects of MS 
pathology. Although ODC degeneration is a hallmark of the disease, reports of 
apoptotic ODCs are highly controversial along the history of MS research and different 
laboratories have challenged the idea of widespread ODC apoptosis in MS, considering 
these events as a minor aspect of the disease [44]. However, a study from Barnett and 
Prineas has recently proposed ODC apoptotic death as the first pathological event in the 
formation of MS plaques [68, 69]. This assumption was based on several autoptic 
histological analyses from MS patients who died shortly after the onset of their last 
relapse. These “early stage” plaques revealed extensive death of ODCs in the presence 
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of reactive microglia, with basically no infiltration of blood-derived inflammatory cells 
(Fig. 11). Consequently, a hypothesis has been put forward proposing MS to be a 
primary neurodegenerative disease in which secondary adaptive immune involvement 
develops. In support of such a scenario it was observed in MRI studies that subtle focal 
changes in the white matter can be observed weeks before a classical new lesion is 
formed [68, 70, 71]. Although these studies put an autochthonous degenerative process 
at the beginning of the disease, it remains unclear how primary loss of ODCs induces 
inflammation. Normally, apoptotic material is considered to have immunosuppressive 
properties and is rapidly removed [72]. Despite this, it has been suggested that extensive 
apoptotic death can overwhelm the clearance of dead cells, allowing immune 
recognition of exposed autoantigens [73] and thus causing the development of 
autoimmunity [74-76]. In this etiological scenario, MS may start with autochthonous 
ODC death resulting in microglia/macrophage activation and antigen leakage into CNS-
draining LNs. Myelin-derived antigens presented in the periphery by APCs, that might 
have received additional inflammatory/danger signals, would lead to clonal expansion 
of CNS-reactive T cells. These could finally invade the CNS and drastically amplify 
myelin damage (Fig. 12), leading to full immunity-driven MS. In order to model this 
hypothesis, we have developed the oDTR mouse model of inducible ODC death (see 
Results). However, other animal systems exist in which ODC death and demyelination 
play a primary role, and are briefly summarized in the following section. 
 
Animal models of demyelination and neuroinflammation 
 
To understand the processes of neuroinflammation and demyelination, several animal 
models of chemically-induced or immune-triggered ODC depletion have been 
developed over the years (Fig. 13). Among the chemically-induced ones, administration 
of the toxin bis-cyclohexanone oxaldihydrazone (cuprizone) in C57/BL6 mice at 6–8 
weeks of age results in localized dysfunctions affecting primarily the corpus callosum 
and cerebellar areas (superior peduncle). In these areas, extensive demyelination along 
with ODC death, microglia activation with engulfment of myelin, and gliosis are 
observed, with virtually all local neurons showing naked axons and 90% of mature 
ODCs depleted from the areas within 3 weeks of toxin feeding. Cuprizone is a copper 
chelator and has been shown to impair the activity of mitochondrial enzymes such as 
cytochrome oxidase and monoamine oxidase, thus resulting into mitochondrial 
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dysfunctions and subsequent disturbances in energy metabolism. It is still unclear why 
cuprizone uptake results in specific death of ODCs, but the already discussed 
metabolically-demanding maintenance of the myelin membrane might be responsible 
for the selective depletion. Cuprizone intoxication does not activate the peripheral 
immune system. This was clearly shown by the absence of an adaptive anti-CNS 
immune response and by a comparable demyelination pattern in immune-deficient 
animals [77] [78].  
Other chemically-induced demyelination models include ethidium bromide (EtBr) 
injection and lysolecithin administration. Following surgical preparation, a 0.01–0.1% 
solution of EtBr can be stereotactically injected into the thoraco-lumbar dorsal funiculus 
of the spinal cord or in the caudal cerebellar peduncle causing local acute demyelination 
within 48 hours. EtBr can also be injected in the subarachnoid space of Sprague–
Dawley or Wistar rats thereby causing demyelination of the optic nerves and the 
chiasm. The size of the lesion and the timing of demyelination depend both on drug 
concentration and injection volume. As EtBr is an intercalating DNA agent, the lesion 
extends to other local cell types such as astrocytes, which are strongly depleted within 
the lesion.  
Lysolecithin is a detergent-like membrane solubilizing agent that can be stereotactically 
injected into the CNS as a 1% solution. Lysolecithin administration results into 
demyelinating lesions in adult mice or rats, with local myelin completely removed 7 
days after lesion trigger [79, 80]. No death of astrocytes or axons is observed in this 
demyelinating model, and most OPCs are spared during lesion production [81].  
While all these models do not result into a strong activation of the immune system, 
proper investigation of anti-CNS immunity has been aided by the animal model 
experimental autoimmune encephalomyelitis (EAE). EAE is induced through 
subcutaneous injection of myelin self-peptides belonging to the proteins MOG [82], 
MBP [83], or PLP [84] mixed with bacterial adjuvant (Complete Freund Adjuvant, 
CFA) in susceptible animal strains [85]. In addition, the concomitant administration of 
pertussis toxin (PT) is often used to enhance disease incidence and severity.  
EAE originates from Pasteur’s experiments with rabies vaccination in the late 19th 
century. The first injections of the vaccine, constituted by spinal cord extracts from 
rabies-infected rabbits, resulted in protection from rabies while affecting a small 
proportion of patients with a progressive ascending paralysis [86]. Years later, the 
association between this severe side-effect and a immune response was found and the 
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administration of CNS lysates together with CFA started to be a classical approach for 
studying demyelinating diseases such as MS. The latter and EAE have in common the 
presence of multiple white matter lesions and their perivascular localization, the 
presence of immunoglobulins, the timing of demyelination, and the destruction of 
myelin sheaths with relative preservation of neuronal structures. The pathogenesis and 
pathology of EAE vary considerably depending on the animal model and on the 
immunogenic peptide used. After EAE induction through sub-cutaneous myelin peptide 
and adjuvant applications, auto-aggressive T cells are first activated in the periphery 
where they become encephalitogenic. Subsequently, these pre-activated cells migrate to 
the CNS where they must be re-stimulated through binding of their cognate antigen on 
local competent APCs, finally initiating inflammatory cascades leading to tissue 
destruction. During EAE, death of ODCs is widely observed and seems to be partially 
responsible for demyelination and axonal death [87]. However, the mechanisms behind 
this degeneration are still not well defined, and both necrotic and apoptotic processes 
seem to be implicated [88, 89].  
EAE has been fundamental in the understanding of different aspects of immune 
activation, tissue destruction, and in the development of some anti-inflammatory MS 
therapies (such as natalizumab or glatimer acetate). However, most promising drugs 
elaborated from EAE studies have failed clinical application. The conundrum of EAE 
efficacy in designing drugs to treat MS is exemplified by IFNγ treatment, which showed 
a protective role in EAE but strongly aggravated disease when administrated in MS 
patients [90]. Also, EAE studies mainly lead to the development of anti-inflammatory 
therapies, which are not efficient in the treatment of progressive forms of the disease 
characterized by low inflammation. Thus, albeit the most used MS model up to date, 
EAE is far from recapitulate the human disease and, being an inducible model, it also 
cannot be used to investigate the triggering phase of the pathology. In my opinion, these 
severe limitations should encourage the development of better models in the future of 
MS research. 
 
Remyelination 
 
Myelin destruction in the CNS naturally leads to remyelination, a process in which de 
novo-produced myelin enwraps demyelinated axons restoring saltatory conduction and 
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resolving functional deficits. The first evidence for this process was given in 1961 by 
the Bunge group, which showed that remyelination was ultrastructurally similar to 
developmental myelination [13]. More precisely, remyelination enwraps naked axons 
with a thinner and shorter myelin layer that the one built-up during primary 
myelination. Since this event results in an increased axonal g-ratio, the latter constitutes 
an important tool allowing investigators to distinguish normally myelinated versus de 
novo remyelinated axons in the context of demyelinating disorders. However, the 
mechanisms behind this structural difference are still unclear [43].  
Remyelination has been thoroughly studied in different animal models of 
demyelination. Synthetically, these studies showed that the process is quite efficient and 
that is able to restore complete functionality in an age-dependent manner [43]. In the 
cuprizone model, spontaneous remyelination is evident starting 6 weeks p.a., and 
removal of the toxin from the diet results into complete lesion remyelination within 3 to 
4 weeks. Spontaneous remyelination also occurs in the EtBr and lysolecithin 
demyelination models, with tissue repair becoming extensive 3 months following lesion 
production in the EtBr model, and being slightly faster following lysolecithin 
administration [81].  
Importantly, remyelination seems to be less effective in the inflamed CNS of the EAE 
model and in human MS. In the latter disease, complete remyelination is observed in 
many early acute lesions but tissue repair becomes utterly insufficient as lesions become 
chronic, thus resulting in the accumulation of clinical disabilities (see Oligodendrocyte 
support of axonal integrity section). 
Remyelination is performed by newly-matured ODCs derived from the OPC pool, 
which is constituted by highly frequent cells (9% of parenchymal cells) homogenously 
distributed between white and gray CNS matter, and characterized by the expression of 
NG2 and PDGFRα markers [91-94]. OPCs can also derive directly from the stem cell 
pool of the SVZ, as it was shown for cells from different precursors stages which could 
migrate to the injured corpus callosum and start a remyelination program in situ [21, 
95]. Also, the latter process seems to have relevance for human pathologies as it was 
observed that cells in the SVZ display higher rates of proliferation and increased 
number in MS patients compared to controls [43]. OPC activation, migration and 
proliferation strongly rely on astroglia- and microglia-derived factors as IGF-1, FGF 
and PDGF. These lead to a phenotype switch in which several genes related to 
developmental myelination become upregulated. Nonetheless, the developmental 
30 
 
production of myelin was proven to differ consistently from the remyelination process, 
with Notch and Olig1 proven dispensable for the latter. Also, inflammation plays a 
primary role. The presence of activated phagocytic cells as microglia and macrophages 
seems to be essential as it results into local production of inflammatory mediators like 
IL1β, TNFα, LT, and MHC-II, all proven to be important for remyelination efficiency 
[43]. Moreover, chemically-induced demyelinating models clearly show that 
macrophage- and microglia-mediated removal of myelin debris is essential before repair 
[96], as presence of myelin seems to strongly inhibit the repair process both in vitro and 
in vivo. 
However, despite extensive inflammation, remyelination fails in chronic MS. This 
phenomenon cannot be explained by mere lesion area, insult chronicity per se, and 
failure in OPC activation and recruitment, as several studies have consistently proven a 
diffuse presence of OPCs within areas of demyelination. Rather, remyelination failure 
could be attributed to the properties of the chronic lesions, with the hypothetical 
presence of myelination-inhibitor factors and absence of pro-remyelination factors. 
Accordingly, chronic lesions show a much lower inflammatory activity than acute ones 
and produce less pro-remyelination inflammatory mediators [43]. 
As for mature ODCs, their remyelination capability is still unclear. Earlier observations 
in MS lesions seemed to show some degree of mature ODC proliferation within 
remyelinating areas [97], and in vitro ODCs were shown to regenerate damaged myelin 
processes and to display some degree of migratory capability after maturation [97]. 
Mature ODCs have also been shown to extend their processes and to produce some 
myelin membranes, albeit in a limited fashion and never directly enwrapping axons [93, 
98]. Altogether, these observations support an interesting hypothesis in which in vivo 
mature ODCs would maintain a certain degree of structural plasticity possibly enhanced 
within CNS pathologies. Nonetheless, several studies failed to prove this point and 
transplanted mature ODCs were shown to lack the ability for tissue repair in different 
experimental approaches [91, 99, 100] [101]. Thus, although still a matter of debate, 
several evidences show that remyelination in the CNS is performed by the sole OPC 
pool. 
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IGF-1 functions in ODCs and demyelinating diseases 
 
The IGF-1/IGF1R signalling pathway is one of the main players in controlling cells of 
the ODC lineage. Its involvement in myelination and neuroprotection has been under 
investigation for several years. IGF1R has three natural ligands in IGF-1, IGF-2, and 
insulin, although the last two molecules bind with extremely low affinity to the receptor 
[102]. The latter is expressed by virtually all resident cells of the CNS and by invading 
inflammatory cells as macrophages and lymphocytes. In the periphery, IGF-1 is under 
the control of growth hormone and is mainly produced by the liver. In the CNS, IGF-1 
is mostly produced by ODCs, microglia, and astrocytes in a paracrine manner. IGF1R is 
a member of the transmembrane tyrosine kinase family and it comprises two αβ 
subunits linked together by disulfide bonds. In this structure, the α subunit provides an 
extracellular binding site for the ligand while the β subunit comprises an intracellular 
site for tyrosine autophosphorylation upon ligand binding [103]. Activation of the 
receptor results in recruitment of the Irs-2 binding protein and in intracellular signalling 
cascades which can involve Ras/MAPK, PI3K/Akt, and mTOR pathways. Interestingly, 
IGF-1 signalling is tightly regulated by a complex homeostatic system of IGF-binding 
proteins (IGFBPs) and IGFBP-proteases, which regulate factor stability and localization 
[102].  
During development, IGF-1 and IGF1R are widely expressed throughout the CNS [104, 
105]. It was shown that transgenic IGF-1 overexpression promotes myelination in 
development [100, 106-108], while absence of the receptor on ODC progenitors led to 
hypomyelination and reduced brain size [101]. It is, however, currently unclear whether 
IGF1R signalling in ODCs is also a requirement for successful remyelination after 
myelin damage. Recently, several groups showed that IGF-1 acts as a post-traumatic 
neuroprotective and myelogenic agent [106, 109-113], although in other studies [101, 
114] such an effect was not observed. IGF-1 signalling has been implicated in enhanced 
survival in virtually all cell types. In the CNS, IGF-1 is strongly neuroprotective in 
animal models of ischemia, axotomy, age-induced hippocampal neuronal death, 
dopamine-induced granule cell death, cortical neuron apoptosis by serum deprivation, 
and glutamate-induced motor neuron apoptosis [115]. Also, IGF1R was shown to 
directly protect immature ODCs from apoptosis in vitro [116] and in vivo in different 
experimental conditions as TNFα-induced injury and cuprizone-mediated intoxication 
[106]. In the latter model, cuprizone-induced ODC death triggers per se IGF-1 
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upregulation in the surrounding parenchyma [117-119]. IGF1R signalling may also play 
an important function in MS, as surviving ODCs surrounding sclerotic lesions 
upregulate IGF1R and IGF-1, indicating a role of this pathway in response to 
inflammatory demyelination [120]. However, in the EAE model, the role of IGF1R on 
ODCs is hotly debated because of the contrasting results published in literature. While 
some works show that expression of IGF-1 in the CNS failed to protect mice from EAE 
[121], or even worsened the disease [114], other reports [122] [113] [123] showed 
transient clinical amelioration and slightly improved remyelination during acute EAE. 
Yet another study [124] showed reduction of number and area of demyelinating EAE 
lesions. Nonetheless, none of these studies displayed cell-specific deletion of IGF1R or 
specific delivery of the growth factor to certain cell types, thus preventing the reader 
from drawing any specific conclusion. In fact, since IGF1R plays a role in most cell 
types in EAE, and it was shown to exert important effects on encephalitogenic T cells 
and activated glia [125], data interpretation in the absence of specific genetic 
manipulations becomes virtually impossible. Thus, new animal models bearing 
deletions of IGF1R on distinct cell types would allow better understanding of this 
signaling pathway in ODCs, both in steady state and under demyelinating stress. 
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Fig.1 – Del Rio-Hortega’s four types of glia.  
A: Gray matter protoplasmic neuroglia. B: White matter fibrous neuroglia. 
C: Microglia. D: White matter interfascicular glia (ODCs)  
 
Fig.2 – Astrocyte and microglia morphology.  
On the left, GFAP-specific immunostaining (green) and DAPI nuclear staining (blue) 
show the typical appearance of parenchimal astrocytes. On the right, Iba1-specific 
staining (brown) depict the ramified morphology of resting microglia. 
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Fig.3 - Visual representation of an oligodendrocyte.  
The cell is wrapping different axons (A) in between nodes of Ranvier, the only 
axonal regions in which the extracellular space (ES) is accesible to neurons. Note 
the multi-layered disposition of the myelin sheath and the small cytosolic content 
(cyt) within the wrapping membranes. 
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Fig.4 – Cell differentiation in the ODC lineage 
Different stages in ODC differentiation are here depicted with the main 
markers expressed per cellular stage. 
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Fig 5 – Hematopoiesis. 
Here represented the process of hematopoiesis, which illustrates the development of 
the immune system from a common bone-marrow precursor named hematopoietic 
stem cell (HSC). HSCs develop further into a lymphoid and a myeloid progenitors, 
which give respectively rise to the premature cells of the adaptive and the innate 
arms of the immune system.  
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Fig.6 – Positive and negative T cell selection in the thymus. 
Pre-T cells continue their development from lymphoid precursors migrating from the 
bone marrow to the thymus. Within the latter, different developmental “double 
negative (DN)” stages precede the expression of a TCR in the “double positive (DP)” 
CD4+ CD8+ stage and the following positive selection by cortical epithelial cells in 
the thymic cortex. Surviving cells procede to a single positive (SP, either CD4+ or 
CD8+) stage in which they are tested for autoreactivity in a negative selection 
exerted by medullary dendritic cells. Only surviving thymocytes can migrate to the 
periphery as naïve T cells. 
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Fig.7 –The immunological synapse. 
The image represents the so-called immunological synapse, a cell-to-cell 
signaling in which T cells can recognize through their specific TCRs their 
cognate antigen presented in the context of MHC-I (left) and MHC-II (right) 
molecoles by APCs. As depicted in the image, CD4 and CD8 on helper and 
cytotoxic T cells respectively act as co-receptors in the specific interactions with 
MHC-I or MHC-II molecules. 
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Fig.8 – The neuroimmune balance.  
Immune cells during inflammation are potentially capable to mediate both 
neurodestruction and neuroprotection. The final outcome of this balance depends 
on the particular interplay of in situ signaling. 
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Fig 9 –MS lesions and perivascular cuffs. 
On the left, a) Axial image from T2-weighted sequence shows multiple lesions in white 
matter tissue. b) Sagittal T2-weighted FLAIR image. Areas of corpus callosum displaying 
brain edema and demyelination appear high in signal. c) Sagittal T2-weighted image 
showing lesion in the mid-thoracic spinal cord. d) Gadolinium-enhanced sagittal T1-
weighted image revealing focal areas of BBB disruption, here high in signal. On the 
right, a perivascular cuff of mononuclear cells in NAWM of a RR-MS patient as detected 
by H/E staining. 
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Fig 10 – Cells mediating ODC injury within MS lesions. 
Different cells can damage ODCs through the release of inflammatory soluble 
mediators affecting the target cell directly or through 
astrocytes/microglia/macrophages. Other cells, as γδ T cells and cytotoxic T 
cells, can lyse directly ODCs through the release of perforin and granzymes. 
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Fig.11 – ODC apoptosis as an hallmark of early sclerotic lesions. 
On the left, medullary demyelinated lesion of a patient who died 17 hours after the 
symptomatic onset of the lesion. In no area myelin loss is complete. On the right, 
morphology of apoptotic ODC nuclei in prephagocytic areas. All show a reduction in 
nuclear volume together with condensed chromatin. 
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Fig.12 – A neurodegenerative hypothesis for MS pathogenesis. 
ODC death (step 1) leads to release of myelin antigens (step 2) to CNS-draining 
lymph nodes, where autoreactive T cells are primed by APCs activated by a danger 
signal (step 3). Myelin-specific T cells expand clonally (step 4) and migrate to the 
CNS (step 5) triggering further tissue destruction. 
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Fig.13 – Animal models of demyelination.  
The table summarizes the main chemically-induced and neuroinflammatory animal 
models for demyelination. The typical species used in research, the timing and quality 
of the demyelination insult are also depicted in the table. The last column to the right 
recapitulates the known remyelination scenarios in the different models.  
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SPECIFIC AIMS 
 
Oligodendrocytes (ODCs) are important players in most degenerative and inflammatory 
pathologies of the CNS. However, little is known about the direct influences of ODC 
damage and death on immune activation. Also, utterly unclear are the intrinsic ODC 
responses within inflammatory environments, and the degree of neuronal impairment 
without ODC support. With the work presented in this thesis, I intend to investigate 
these essential issues:  
 
a) Studying the impact of ODC death on adaptive immunity and neuronal survival 
 
We wanted to test the neurodegenerative hypothesis for MS pathogenesis in a mouse 
model of inducible ODC death, the oDTR strain. ODCs marked with a transgenic 
diphtheria toxin receptor were specifically killed through DT application. This allowed 
to analyze the activation status of innate and adaptive immune cells in a time-controlled 
manner following ODC death. In addition, different immune activation paradigms could 
be applied following ODC death and their impact on the immune response could be 
followed. 
 
b) Understanding the role of IGF1R signaling in adult ODCs under demyelinating 
conditions 
 
IGF1R signaling affects survival, metabolism and myelination in the ODC lineage. 
Through our animal model (oIGF1R) we wanted to define the importance of this 
pathway in post-mitotic ODCs and to understand the unclear role of ODCs in the 
pathogenesis and damage progression of autoimmune-inflammatory diseases such as 
EAE and MS. 
 
c) Developing a mouse model to quantify in vivo demyelination and remyelination 
 
In demyelinating disease models, quantification of ODC death and myelin loss is 
possible only through analyses of autoptic material. We generated and evaluated a new 
animal model (oLucR) in which the expression of luciferase within mature ODC was 
expected to allow in vivo quantification of myelin and thus permit the study of 
demyelination insults and tissue repair. 
46 
 
MATERIAL AND METHODS 
 
Animal Maintenance and Genotyping  
 
The animals were kept under SPF conditions according to Swiss animal law and 
institutional guidelines. Presence of respective transgenes was confirmed by PCR 
analysis on DNA from tail biopsies by use of the following primer pairs: MOGi-cre 
(WT 350 bp) GAC AAT TCA GAG TGA TAG GAC CAG GGT ATC CC and GCT 
GCC TAT TAT TGG TAA GAG TGG; MOGi-cre (knock-in, 700 bp) 
TCCAATTTACTGACCGTACAC and CATCAGCTACACCAGAGACGGAAATC; 
iDTR (WT 600 bp, KI 845 bp) AAA GTC GCT CTG AGT TGT TAT, GGA GCG 
GGA GAA ATG GAT AAA GTC GCT CTG AGT TGT TAT, GGA GCG GGA GAA 
ATG GAT ATG, and AAT AGG AAC TTC GTC GAG AAT AGG AAC TTC GTC 
GAG C; IiMOG GGC TAC TGC TGA CTC TCA ACA TT, ATT TCG GTA GAG 
GTG AAC CAC GGC TAC TGC TGA CTC TCA ACA TT , ATT TCG GTA GAG 
GTG AAC CAC TC, and CAG GGT TTC CTT GAT GAT GGT TTC CTT GAT GAT 
GTC (WT 456 bp, KI 982 bp); deleter-cre GAA AGT CGA GTA GGC GTG TAC G 
and CGC ATA ACCAGT GAA ACA GCA T (600 bp). 
 
Disease models 
 
For EAE experiments 6 to 10 week old mice were immunized subcutaneously with 200 
µg (each flank 100 µg) of myelin oligodendrocyte glycoprotein MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK, Invitrogen) emulsified in Complete Freund’s 
Adjuvant (CFA, H37 Ra, Difco laboratories), followed immediately and at day 2 by i.p. 
injection of 200 ng pertussis toxin (Sigma). To induce ODC apoptosis through DT 
administration, where not differently reported, oDTR and control animals were injected 
i.p. with 200 ng DT (Merck) daily over 7 days. Gender-specific differences regarding 
disease onset or progression were never observed. For activation of APCs and depletion 
of Treg cells anti-CD40 (FGK4.5, Bioexpress) and anti-CD25 (PC-61, Bioexpress) 
antibodies were used.  
In the RotaRod experiments, the mice were placed on the rod in three consecutive trials 
with an acceleration from 5 to 50 rpm in 3 min and time to fall was recorded. In the 
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walking grid assay we counted the number of footfalls in each crossing over a 50 cm-
long runway with irregularly arranged bars (0.5-2.5 cm) on a distance of 10 cm, fixing 
the maximum amount of errors as 10. The EAE score was calculated as follows: 0, no 
detectable signs of EAE, 0.5, distal limp tail; 1, complete limp tail; 1.5, limp tail and 
hind limb weakness; 2, unilateral partial hind limb paralysis; 2.5, bilateral partial hind 
limb paralysis; 3 complete bilateral hind limb paralysis; 3.5, complete hind limb 
paralysis and unilater forelimb paralysis; 4, total paralysis of fore and hind limbs; 5, 
death. Tremor was measured on a scale from 0-3, with 0, representing total absence of 
tremor; 1, slight tremor observed during motor tests; 2, strong tremor observed during 
motor tests, slight tremor during normal behavior; 3, strong tremor observed during 
motor tests and during normal behavior. To assemble the different data in the 
combinatorial score, each measurement was first re-calculated into percentages, 
assuming the weight and RotaRod score measured before DT administration, a grid 
walking test without error, and absence of tremor as 100%. 
 
Cell Culture and Flow Cytometry 
 
For in vivo proliferation experiments cells were prepared from LNs and spleens of 2D2 
mice, underwent erythrocyte lysis (BD Biosciences) and were purified by MACS using 
CD4 microbeads (Miltenyi Biotech). Subsequently, they were incubated with 1 ml 
CFSE solution (5(6)-CFDA,SE, Invitrogen, 5 µM in DMEM) per 107 cells for 10 min at 
37°C. The reaction was stopped with 10 ml ice-cold FCS and after washing with 
phosphate buffered saline (PBS), 107 of the cells were injected i.v. in 200 µl PBS.  
For flow cytomentric analysis of CNS-invading cells, mice were killed with CO2 and 
perfused intracardially with PBS. Spinal cord and brain were removed, mechanically 
homogenized, and strained through a nylon filter (70 µm, SPL lifesciences). After 
centrifugation, cells were resuspended in 30% Percoll (Pharmacia) and centrifuged at 
18,500 g for 30 min, 4°C. The interphase was collected, the cells were washed and 
treated with Fc-block (1 µg per 106 cells, 2.4G2) before staining. Fluorescence staining 
was performed as previously described [126]. The following antibodies were purchased 
from BD: 53-6.7 for CD8, N418 for CD11c, H57 for TCRβ, 7AD/PC61 for CD25, IM7 
for CD44, 30-F11 for CD45, MEL-14 for CD62L M1/70 for CD11b, M5/114 for 
MHCII; from Biolegend: RM4-5 for CD4; from eBiosciences: BM8 for F4/80 and FJK-
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16s for Foxp3. Dead cells were excluded by LIVE/DEAD® Fixable Dead Cell staining 
(Invitrogen), Topro-3 (10 nM, Invitrogen), or Propidium Iodide (0.2 mg/ml, Sigma-
Aldrich). Analysis was performed on a FACSCantoII (BD Biosciences) and analyzed 
by FlowJo software. For radioactive proliferation assays we placed 2 105 LN cells per 
well in complete IMDM in a 96-well. Cells were plated as quadruplicates and pulsed 
with 60 µg/ml MOG35-55 (Genscript), 20 µg/ml PLP protein (AbD serotec), 20 µg/ml 
MBP protein (Chemicon international), 10 µg/ml concanavalin A (Sigma-Aldrich), 5 
µg/ml anti-CD3e (2C11, BioXcell) or 5 µg/ml anti-CD28 (37N, Bioexpress). After 48 h, 
cells were pulsed with 3[H]-thymidine (GE healthcare; final concentration 5 µCi/ml) 
and incubated for an additional 24 h before they were harvested and thymidine 
incorporation was assessed using a cell harvester (Perkin-Elmer) and Wallac 1450 
Microbeta scintillation counter (Perkin-Elmer). 
Histology  
 
Mice were euthanized with CO2 and perfused with PBS. For cryosections, brain and 
spinal cord were isolated, embedded (Mdite), frozen on dry ice and stored at -80°C. 
Tissues were cut sagittally at 10 µm and thaw-mounted onto glass slides (Menzel 
GmbH). Sections were air dried over night, fixed with 4% paraformaldehyde (PFA; 
AppliChem) for 10 min and washed 3x with PBS. The TUNEL staining was performed 
after antibody stainings using the In Situ Cell Death Detection Kit (Roche) according 
the manufactures guidelines. For vibratome sections the tissue was fixed overnight with 
4% PFA, cut sagittally in 40 µm thick sections and stained as described before (Spergel 
et al., 1999) with antibodies or antisera against following antigens: GFAP (DAKO), 
aspartoacylase (ASPA; rabbit polyclonal serum, Dr. Matthias Klugmann, Mainz, 
Germany), proteolipid protein (PLP; rat, homemade), F4/80 (rat, homemade) nerve glia 
antigen 2 (NG2; rat monoclonal, Dr. Jacqueline Trotter, Mainz, Germany) and  ionized 
calcium binding adaptor molecule 1 (Iba1; rabbit, Wako Pure Chemical Industries). 
Detection was accomplished using either horseradish peroxidase-conjungated secondary 
antibodies or biotinylated secondary antibodies, streptavidin-horseradish peroxidase 
(Vector Laboratories) and 3,3`diaminobenzidine (DAB; Sigma-Aldrich Fluka). A 
MHC-class-II-specific antibody (rat, BD Biosciences) and tomato lectin (FITC 
conjugated, Sigma-Aldrich) were used for immunofluorescence. Secondary antibodies 
were labeled with Cy3 or FITC (Dianova). Sections were covered with Vectashield 
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(Vector Laboratories) and analyzed by confocal (Leica SP5) or fluorescence (Olympus 
BX50) microscope. For paraffin sections, animals were additionally perfused with 4% 
PFA in PBS. Brain and spinal cord were fixed in 4% PFA for additional 3 to 12 hours. 
Tissues were embedded in paraffin and 5µm thick paraffin sections were cut. 
Deparaffinized sections were stained with hematoxylin-eosin (H/E), Nissl as well as 
Luxol Fast Blue and Periodic Acid Schiff (LFB/PAS) according to standard protocols. 
Briefly, for H/E and myelin staining, paraffin slices were dewaxed with xylol, 
rehydrated and stained with hematoxilin 7211 and eosin Y (Microm International). For 
myelin staining, a LFB-solution (0.1% LFB in 95% isopropanol containing 0.05% 
acetic acid, stained overnight at 60°C) and hematoxylin (stained for 1 minute at room 
temperature; Microm international) were used. Lithium carbonate solution (0.05%) was 
used for color differentiation of the LFB. Myelin-degradation products were detected 
with 0.3% (w/v) oil-red O (ORO) (Gurr) in 60% 2-propanol and counterstained with 
hematoxylin. Immunohistological staining to ionized calcium binding adaptor molecule 
1 (Iba1; rabbit, Wako) and CD3 (Neomarkers Thermo Scientific) was performed by a 
Ventana Benchmark XT automated staining according to manufacturers guidelines. For 
NF staining, paraffin sections were first dewaxed and rehydrated followed by antigen 
retrieval in citrate buffer pH 6,0 for 10 minutes. Sections were then incubated in 0,3% 
of hydrogen peroxide and blocked with 3% NGS and 0,3% Triton X100 in PBS. NF-
specific antibody (Millipore) was incubated for 12 hours at room temperature. A 
biotinylated secondary antibody (goat anti-ms, Vector) was used for detection. The 
staining with DAB was developed using Vectastain ABC kit (Vector) according to the 
manufacturer’s protocols. Sections were counterstained for two minutes with hemalaun 
(Dr. Hollborn and Sons). 
Transmission electron microscopy 
 
Anaesthetized mice were perfused with PBS followed by freshly prepared 1% (v/v) 
glutaral aldehyde (GA), 2% (w/v) paraformaldehyde and 0.2% (v/v) picric acid in 0.1 M 
phosphate buffer, pH 7.4. Brain regions as indicated were taken and post-fixated in 
2.5% GA in PBS for 1h followed by fixation with 2% osmium tetroxide in PBS for 2h. 
Samples were then dehydrated using the automated tissue processor Leica EM TP 
(Leica) and were embedded in Epon at 60°C for 48h. 70 nm ultra-thin sections were 
stained with 4% uranylacetate and lead citrate as described previously [127]. Samples 
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were visualized using a Phillips CM 100 transmission electron microscope (FEI) 
equipped with a digital Gatan 4k x 3k camera (Gatan Inc.). 
Iodine labeling of MOG-specific antibody and radioactivity detection 
 
Na125I (629 GBq/mg, Perkin Elmer) was activated in a Pierce pre-coated iodination tube 
(Thermo Scientific) and then mixed with MOG-specific antibody (818C5, homemade). 
The reaction was stopped with a saturated solution of tyrosine (10 mg/ml) and the 
antibody purified through a 10 ml polyacrylamide desalting column (Thermo 
Scientific). Fractions containing the purified antibody were identified on a nitrocellulose 
membrane and pooled. 12 hours after the injection of the 125I-antibody, mice were 
sacrificed, perfused and CNS was analyzed for antibody incorporation in a Kontron 
Gamma-matic (Sertec electronics). 
Immunoblotting 
 
Mouse tissue was digested in lysis buffer (Tris-Cl 35mM, NaCl 150mM, NP-40 1%, 
Sodium deoxycholate 0.5%, Triton 1%, Na3VO4 1mM, leuptinin 1ug/ml, NaF 5mM, 
PMSF 5mM) for 30’, sonicated and centrifuged at 13000 rpm at 4°C for 20 min. Protein 
concentration was quantified with a BCA assay (Thermo Scientific). Proteins were 
detected with anti-Vinculin (Cell Signaling), anti-MOG (818C5, homemade), anti-MBP 
(Santa Cruz), anti-NG2 (Millipore). Samples for anti-NG2 immunoblotting were 
previously digested with Chondroitinase ABC (Seikagaku) for 1 hour at 37°C. 
Organotypic cerebellar slice cultures 
 
After sacrifice of P9 pups the cerebellum was extracted and cut 350 μm thick. The 
tissue was immediately collected in dissecting medium (1mM kynurenic acid in HBSS 
containing 100U/ml penicillin and 100 mg/ml streptomycin) where the slices were 
separated from each other under a microscope. Slices were transferred into washing 
medium (HBSS:MEM = 1:1 both with P/S and 25nM HEPES) on ice. The slices were 
finally transferred on cell culture inserts (Millipore) with 1ml slice culture medium (for 
400 ml: 100ml heat inactivated-horse serum, 100ml HBSS containing 100U/ml 
penicillin and 100mg/ml streptomycin, 200 ml MEM containing 100U/ml penicillin and 
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100mg/ml streptomycin, 4ml 50% glucose, 2mM L-glutamine) and then incubated at 
37°C and 5% CO2. The medium was changed every 2 days. 
 
RNA isolation 
 
Samples were homogenized in 1ml TRIZOL and incubated for 5min at room 
temperature (RT). 200μl chloroform per sample was added, incubated for 3min at RT, 
and centrifuged at 8000 rpm for 15min at 4°C. The aqueous phase containing RNA was 
transferred into a fresh tube and precipitated adding 500μl isopropyl alcohol after 10min 
incubation at RT and centrifugation at 800 rpm for 10min at 4°C. The supernatant was 
removed and the RNA pellet washed with 1ml 75% ethanol. Samples were centrifuged 
at 5000 rpm for 5 min at 4°C and the RNA pellet then was let drying out for 15min at 
RT. The RNA was finally dissolved in 45μl RNase free water with 5μl of 10x 
incubation buffer and 1μl DNAseI. The samples were incubated at 37°C for 20min, then 
1μl 0.5 M EDTA was added and incubated at 75°C for 10min and finally chilled on ice. 
 
cDNA synthesis 
 
1μl random primers (100ng/μl), 1μl dNTP (10 mM), 4μl First-strand buffer (5x), 2μl 
DTT (0.1 M), and 1μl RNase OUT were incubated for 2min at 37°C and then 1μl M-
MLV RT (200U/μl) was added. 
5 μg RNA was diluted in 10μl RNase free H2O, heated to 65°C for 5min and quenched 
on ice. Afterwards, 10μl Master Mix were added to the RNA, incubated 10 min at 21°C, 
50 min at 37°C and finally 15 min at 70°C. The cDNA was finally diluted 1:10. 
 
RT-PCR  
 
5μl of cDNA per real time reaction were mixed with 12.5 μl SYBR Green, 6.5 μl H2O, 
0.5 μl F-Primer, 0.5 μl R-Primer for a total volume of 25 μl. The RT-PCR was 
performed in BIORAD machine with the following primers: 
β-actin, F: AGAGGGAAATCGTGCGTGAC; R: CAATAGTGATGACCTGGCCGT 
Nestin, F: CAAGAACCACTGGGGTC; R: CCCTCCTGGTGATTCCACA 
NG2, F: GTTGGGATGCTTGCTGG; R: TGAAAGCTGCAGAAGCA 
MPB, F: ATCCAAGTACCTGGCCAC; R: CCTGTCACCGCTAAAGAA 
MOG, F: AAATGGCAAGGACCAAG; R: AGCAGGTGTAGCCTCCTT 
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OLIG1,F: ACCAACGTTTGAGCTTGCTT; R: GGTTAAGGACCAGCCTGTGA 
OLIG2, F:AGCAATGGGAGCATTTGAAG; R: CAGGAATTCCAGGGATGAA 
  
Bioluminescence imaging 
 
Bioluminescence was detected in vivo with an ultrasensitive IVIS machine (Xenogen) 
which consists of a cooled charged coupled device (CCD) camera bound to a dark box. 
The mice were anesthetized with isoflurane, shaved and measured 3 times a week after 
intraperitoneal luciferin injection (150mg/Kg). Luminescence signal was quantified as 
photons/s/cm2/steridian (sr) using the LIVING IMAGE software version 2.50 
(Xenogen) and integrated over a period of 2 min. The animals were measured for a 
whole experiment length of 22 minutes and data represent the average of the values 
obtained over the 4-22 minutes periods. To quantify the signal, photon emission was 
obtained from a region of interest (brain, spinal cord, whole body) that was kept in a 
constant area and position during all the experiments. To have a baseline imaging for 
reliable bioluminescence comparison, luminescence recording begun at least 11 days 
before the beginning of the experiment. 
 
Preparation of luciferin for in vivo bioluminescence assay 
 
D-Luciferin Firefly, Potassium salt, 1g (Xenogen Catalog XC-1001) was used for a 
stock solution with a concentration of 30mg/ml diluted in PBS. The solution was 
filtered through a 0.2 μm filter, aliquoted and frozen at -20°C.  
 
Bioluminescence in brain slices 
 
The animals were sacrificed, perfused with PBS and brains were collected and cut in 
half. From one half of the brain 1mm thick slice was made, bathed in 150 μg/ml 
luciferin and recorded for 2 minutes with the IVIS camera.  
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RESULTS 
 
DT-induced ODC death leads to progressive motor dysfunction 
 
To investigate whether ODC death could result in an inflammatory disease of the CNS 
we generated the oDTR model in which specificity of the DTR-mediated cell ablation is 
achieved by an ODC-specific Cre strain (MOGi-Cre) crossed to a mouse strain carrying 
a Cre-inducible DT receptor (iDTR) [89, 128] (Fig. 14a). The toxin induces cell death 
through a well-known mechanism by termination of protein synthesis (Fig. 14b).  DT-
induced clinical disease is dose-dependent with progressive pathology clinically 
characterized by exacerbating ataxia, tremor, kyphosis, and cachexia [129]. Disease 
severity was quantified by measuring weight loss, tremor, and motor coordination (see 
Material and Methods and Fig. 15a). After symptomatic onset at around 5 to 6 weeks 
p.a., clinical manifestations of the disease became rapidly stronger (Fig. 15a). The mice 
lost up to 15% of the starting weight and exhibited increasing ataxia followed by tremor 
and rapid decrease in motor coordination eventually resulting in lethal paralysis. We 
combined these data in one unique composite score (Fig. 15a). DT-treated control 
animals never showed any signs of disease, confirming the specificity of ODC ablation 
in the oDTR system. 
 
ODC death and demyelination follow DT administration in susceptible animals 
 
Clinical disease progression was much slower in our model than in EAE in the same 
genetic background, although it was histologically more severe [129]. Starting one 
week p.a., Nissl-stained sections showed the majority of ODCs featuring shrunk nuclei 
and condensed cytoplasm (Fig. 15b). Similar to the ODCs in lymphocyte-free early 
MS plaques described by Barnett and Prineas [68], these cells died through a caspase-
independent mechanism, as we could detect neither TUNEL+ nor activated Caspase 3+ 
ODCs (data not shown). To better characterize the fate of the dying ODCs we therefore 
performed transmission electron microscopy (TEM) analysis of the murine CNS after 
application of DT. ODCs in the white matter of control mice displayed typical clumped 
chromatin and a large, dark grey cytoplasm full of mitochondria and ribosomes (Fig. 
16). In contrast, electron micrographs of DT-treated oDTR animals showed shrunk 
ODCs with condensed cytoplasm (data not shown) and cells with intense vacuolisation 
54 
 
(Fig. 16). To directly quantify the loss of live ODCs, we stained CNS sections for the 
ODC-specific protein Aspartoacylase (ASPA)[130]. We observed that ODCs in all 
myelin-rich areas of the CNS started to disappear 2 weeks p.a. reaching up to 60% cell 
loss around 5 weeks p.a. (Fig. 17a,b,c). In histological samples of DT-treated oDTR 
mice, significant changes in myelin structure became evident starting 3 weeks p.a., 
with obvious vacuolic alterations in myelin-rich structures as cerebellum, pons, brain 
stem, and spinal cord (Fig. 15b, Fig. 17d) coinciding with pronounced demyelination 
as detected by LFB-PAS and myelin-specific stainings (i.e. PLP, Fig 17d,e). MAG and 
PLP mRNA levels in CNS tissue of DT-treated oDTR mice were dramatically reduced 
already 1 week p.a. (Fig. 18a), while at the protein level myelin oligodendrocyte 
protein (MOG), and myelin basic protein (MBP) amounts reduced more progressively 
(Fig. 18b). Fully demyelinated axons were found by TEM starting 5 weeks p.a. (Fig. 
18c). To find obvious leukocyte infiltrations, we performed H/E staining but failed to 
detect any leukocytes within lesioned areas (Fig. 17d). Evans Blue analysis revealed 
no change in permeability between the blood brain barrier (BBB) of DT-treated oDTR 
and control animals (Fig. 18d). In conclusion, DT-treated oDTR animals show 
efficient and widespread ODC death, which leads to a chronic progressive 
demyelination.  
 
ODC progenitor recruitment and remyelination following induced ODC death 
 
While certain myelin abnormalities lead to axonal degeneration and neuronal death 
[131-133], it is still unclear to which extent the death of ODCs is a direct cause for 
neuronal impairment. Surprisingly, Traka et al showed that widespread ODC death did 
not significantly affect axonal number [134], while a similar study [135] in a 
comparable model clearly showed strong neuronal degeneration following ODC 
depletion. To evaluate the axonal integrity in our model we analyzed NF-stained CNS 
sections 2, 4, and 5 weeks p.a. and found axonal loss in DT-treated oDTR mice starting 
4 weeks p.a. (Fig 19a). A detailed analysis through Fluoro Jade C stainings revealed 
widespread damage to neurons following ODC death (Fig. 19b) with the granular layer 
of the cerebellum showing an earlier involvement (asymptomatic, as shown in Fig. 
15a). Along this line, one week p.a. we found evidence for neuronal death through 
TUNEL+ NeuN+ cells in the granular layer of the cerebellum of DT-treated oDTR 
mice (Fig. 19c). As mentioned above, TUNEL+ ODCs could not be observed. 
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Progressive accumulation of OPCs was observed throughout the CNS starting 3 weeks 
p.a. (Fig. 20a), and NG2 protein levels were significantly higher in oDTR than in 
control brain 5 weeks p.a. (Fig. 20b). Even though the mice ultimately succumb to the 
DT-induced ODC loss, some degree of remyelination took place as shown by g-ratio 
analysis of axons in the corpus callosum of DT-treated oDTR mice (Fig. 20c). 
 
Antigen leakage into CNS-draining lymph nodes 
 
The primary goal of this study was to assess the impact of ODC death on immunity. 
Even though immune responses are generally initiated within secondary lymphoid 
tissues, the sites for initial antigen presentation in MS remain unknown. In EAE, dc and 
lumbar LNs, the draining LNs of the CNS, were implicated in relapses and epitope 
spreading [46]. Myelin-containing dendritic-like cells were also found in these LNs in 
MS, post mortem [136] and ex vivo [137]. Thus, a spontaneous anti-CNS immune 
response might be initiated by antigen release in the CNS-draining LNs as in our 
working hypothesis (Fig. 12). To test the presence of CNS-derived antigens in such 
sites in the oDTR model, we analyzed dcLNs and inguinal LNs three weeks p.a.. In 
OilRedO (ORO) stained sections we detected a significant increase in lipids in the 
dcLNs (from 1.8 ± 0.35 to 12.4 ± 0.63 ORO+ cells per field, p < 0.001) but not inguinal 
LNs of DT-treated oDTR animals (Fig. 21a,b), indicating the transfer of myelin 
material to CNS-draining LNs. To determine whether ORO reactivity represented actual 
myelin antigens, we analyzed protein extracts of lumbar LNs from DT-treated animals 1 
and 2 weeks p.a. and detected increased MBP and MOG protein level specifically in 
DT-treated oDTR mice (Fig. 21c). 
 
Antigen drainage from dying ODCs does not prime myelin-specific T cells 
   
Myelin components in CNS-draining LNs should make myelin epitopes visible to auto-
reactive peripheral T cells. To investigate this, we injected 107 CFSE-labeled T cells 
from the MOG35-55 specific TCR-transgenic mouse strain 2D2 [138] after inducing 
ODC death at different time points. Surprisingly, we observed in none of the DT-
treated oDTR animals proliferation of these myelin-specific T cells (Fig. 21d). 
Since T cells from 2D2 mice were modified to recognize a single epitope of a rather 
scarce myelin protein we decided to increase the amount of cognate antigen by 
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crossing the oDTR strain to the IiMOG strain, leading to increased expression of the 
antigenic MOG35-55 peptide [139] within ODCs. Again, induction of ODC death was 
followed by injection of CFSE-labeled 2D2 T cells. We also applied PT, commonly 
used as enhancer of anti-CNS inflammation, and an agonistic monoclonal antibody 
(mAb) against CD40 (30 µg/mouse at day 5) shown to increase priming of T cells 
[140]. Even under these extremely biased experimental conditions, only 40% of the 
mice showed a minor population of proliferating MOG-specific T cells five days later 
(Fig. 22a, bottom left), while the majority of animals did not show any kind of 2D2 
proliferation (Fig. 22a, bottom right). A fully proliferating T cell population was found 
in all animals expressing MOG35-55 ubiquitously (del-cre/IiMOG) [139] (Fig. 22a, 
upper left).  
Being aware that the 2D2 system narrowed antigen recognition [141], we also 
investigated immune responses toward additional myelin antigens. At d7, d14 and d30 
p.a. cells from inguinal, axillary, and CNS-draining LNs were stimulated in vitro with 
PLP, MBP, MOG35-55 and the irrelevant protein ovalbumin (OVA). No proliferation to 
these antigens was detected after induced ODC death. Only cells of MOG35-55/CFA 
immunized controls showed a response towards MOG35-55 (Fig. 22b). To exclude that 
DT treatments leads to a general impairment of T cell priming, we treated oDTR and 
control animals with DT followed by immunization with either keyhole limpet 
hemagglutinin (KLH, a neo-antigen) or with MOG35-55 in CFA. At 9 days p.i., cells 
were isolated from LNs and stimulated in vitro with KLH or MOG35-55,, respectively. 
Upon restimulation of LN cells from these animals 9 days p.i. we observed unaltered 
proliferative responses towards the immunizing antigens (Fig. 22c) excluding that DT 
would suppress priming. Thus, although we found myelin antigens in CNS-draining 
LNs after induced ODC death, these failed to initiate an anti-CNS response even under 
most biased experimental conditions. 
 
Microglia/macrophage activation and gliosis but no T-cell recruitment after 
induced ODC death 
 
Innate immune cells serve as a first line of defence by immediate clearance of pathogens 
and induce subsequent adaptive immune reactions upon reception of a danger signal 
[142]. The CNS-resident innate immune cell, microglia, make up the main cellular 
fraction within MS plaques (reviewed in [143, 144]). Such reactive 
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microglia/macrophages have the potential to serve as APCs through expression of MHC 
class I, II and co-stimulatory molecules [144]. 
We found that induction of ODC death resulted in progressive accumulation of CD45int, 
CD11bhi, F4/80+ (Fig. 23a) and Iba1+ (Fig. 23b, Fig. 17b) activated 
microglia/macrophage. The activation process started as soon as one week p.a. and 
persisted until the final stage of the disease (Fig. 23a,b). Also morphologically 
microglia/macrophages in white matter areas appeared reactive (Fig. 23c) and showed 
high expression of MHC-II and CD44 (Fig. 23d, 24a). Similarly, an overall progressive 
gliosis was shown by staining for GFAP (Fig. 24b, Fig. 17b). Yet, histological analysis 
showed the CNS of DT-treated oDTR to be devoid of B and T lymphocytes (Fig. 24c). 
Quantification of CNS infiltrating leukocytes by flow cytometry revealed no invasion of 
CD4+ and CD8+ T cells in CNS after induction of ODC death (Fig. 24d). Taken 
together, we observed profound activation of microglia and astrocytes in the affected 
areas, whereas adaptive immune cells were not found to invade the demyelinating CNS. 
 
Chronically induced ODC death does not result in CNS inflammation 
 
MS is a progressively developing disease with sparse focal demyelination. To better 
mimic this aspect of the disease we also tested a strategy leading to a chronic albeit 
more limited death of ODCs. Following a five months-long treatment with a weekly 
low dose of DT (50 ng i.p), we could detect mild demyelination and sparse ODC death 
specifically in oDTR mice (Fig. 25a,b) along with a clear increase in Iba1+ 
microglia/macrophages (Fig. 25c). Clinical presentation in these mice was mild to 
absent (data not shown). Analysis of leucocytes along the course of the treatment (7 and 
15 weeks p.a., data not shown) and at endpoint (19 weeks p.a., Fig. 25d) revealed no 
differences between DT-treated oDTR and control mice. Cells from LNs of both DT-
treated oDTR and genetic control mice failed to show a proliferative response to MOG, 
PLP, MBP, MOG35-55, and total brain homogenate (data not shown). Thus, even chronic 
ODC death and demyelination did not result into an anti-CNS adaptive immunity 
response. 
 
Anti-myelin antibody does not modify the disease induced by ODC death 
 
One of the most important diagnostic hallmarks in MS is the presence of oligoclonal 
58 
 
bands (immunoglobulins) and plasma cells in the CSF [145, 146]. As already 
mentioned, CNS-infiltrating B cell clones were suggested to produce autoantibodies 
[147] damaging and opsonizing myelin membranes and thus aiding myelin-specific T 
cell responses. We and others have previously shown in the EAE model that anti-MOG 
antibodies drastically increase clinical disease in a complement-dependent fashion [148, 
149] and thus wanted to ask whether a similar effect could be achieved in the oDTR 
model. Since we had not detected any increased permeability of the BBB (Fig. 18d), we 
first confirmed that radio-labeled anti-MOG antibody accumulated in the CNS of DT-
treated oDTR animals (Fig. 26a). We then injected oDTR and control animals with 200 
µg of anti-MOG or anti-NP control antibody intravenously at days 14, 21, and 28 after 
DT application. Even though we did not detect any clinical difference between the two 
groups (Fig. 26b), anti-MOG application resulted in slightly higher ODC loss and glial 
activation compared to the anti-NP control group (Fig. 27a,b,c). Yet, again H/E- and 
anti-CD3-stained histological sections (data not shown) failed to reveal any 
accumulation of lymphocytes in CNS from both groups. Thus, in contrast to EAE, the 
application of anti-myelin antibodies does not exacerbate ODC death-induced disease or 
aid the development of anti-CNS immunity. 
 
Bystander activation of APCs does not support development of CNS-autoimmunity 
after ODC death 
 
In order to become activated, auto-reactive T cells must first encounter APCs already 
primed by a microbial trigger and/or a co-stimulatory signal [142]. EAE induction with 
the help of CFA results in a profound anti-CNS immune response, thus emphasizing the 
necessity for a strong danger signal over-riding tolerance [150]. To combine induced 
demyelination with adjuvant-driven immune activation, we treated oDTR and control 
mice with PT and CFA after DT application. Nonetheless, also in this experiment we 
could not observe any signs of EAE-like disease in experimental animals apart from the 
expected clinical degeneration (data not shown). To further enhance sensitivity and 
specificity of the system we crossed the oDTR mice to the 2D2 strain, reported to 
display only 5% incidence of spontaneous EAE [138]. We treated such oDTR/2D2 
animals with DT and CFA/PT to increase spontaneous EAE incidence. In both, 
oDTR/2D2 and MOGi-Cre/2D2 mice a similar fraction developed symptoms of EAE 
(Fig. 28a) with comparable onset and severity (Fig. 28b). Taken together, massive 
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demyelination does not result in anti-CNS immunity even under conditions in which the 
majority of T cells are specific to myelin antigens and lymphocyte activation is 
indirectly aided by adjuvant use. 
Another very strong stimulus to innate APCs is the artificial activation of CD40 
signaling (reviewed in [151, 152]). Since in our model T cells apparently ignored the 
peripheral presence of CNS antigens, we activated APCs specifically by injection of an 
agonistic CD40-specific antibody during the course of DT-induced demyelination. CNS 
from oDTR animals treated with DT and CD40-specific antibody showed strong hyper-
activation of microglia/macrophages (Fig. 27c, Fig. 28c) and astroglia (Fig. 27b), either 
due to antibody entry or through a peripherally induced cytokine storm. Also, double-
treated animals displayed a slight reduction in ODC density compared to DT-only 
treated oDTR animals (Fig. 27a). Nevertheless, no clinical difference between the 
groups became apparent (Fig. 28d) and no parenchymal or perivascular accumulation of 
lymphocytes were detected in the demyelinated CNS (data not shown). Again, no 
specific lymphocyte response follows ODC death and strong activation of the immune 
system. 
 
Absence of CNS inflammation is not due to T cell tolerance 
 
As briefly discussed, self-reactive T cells are eliminated from the circulating pool 
through the thymic process of negative selection. Yet, as some clones usually evade this 
deletion process, different other mechanisms exist to limit the activation of autoreactive 
T cells. For instance,  antigen recognition within a non-inflamed environment can lead 
T cells to deletion or to a state of immunological unresponsiveness named tolerance 
[153]. We therefore performed experiments to exclude that such tolerance prohibited the 
generation of an anti-myelin specific immune response in the oDTR model. First we 
tested whether induction of ODC death interfered with EAE induced by active 
immunization. oDTR mice and controls were treated with DT or BSA and then 
immunized with MOG35-55 in CFA (d0), with or without co-injection of PT (d0 and d2). 
The clinical disease course was not ameliorated but slightly more severe in MOG35-55 
immunized oDTR animals in comparison to control animals (Fig. 29a), although 
disease incidence was equal in both groups (Fig. 29b). Moreover, a similar number of 
inflammatory infiltrates with equal activation states were found at disease onset by flow 
cytometry (data not shown). Taken together, no indication of tolerance was found in 
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these experiments. We performed an additional experiment in which CD90.2+ 
oDTR/IiMOG and MOGi-Cre/IiMOG control mice received 107 CD90.1+ CFSE-labeled 
2D2 T cells after induction of ODC death. One day after the cell transfer, half of the 
mice from both groups were tolerized by injection of MOG35-55 in PBS. At day 6 after 
the initial cell transfer, all animals were immunized by subcutaneous administration of 
MOG35-55 in CFA. Ten days later, tolerized animals showed a reduced number of 
CD90.1+ proliferating cells in LNs and spleen (Fig. 29c); however, this reduction was 
not affected by DT application in oDTR mice. Thus, MOG protein released from dying 
ODCs does not induce tolerance against the peptide MOG35-55. 
Lastly, to release unbridled T cell immunity, we deleted Tregs [154] . Although MS 
patients do not show a reduction in Tregs, defective suppressive activity of this 
population was observed in a number of studies [155, 156]. We removed Tregs after 
induction of ODC death using anti-CD25 mAbs (PC61)[154] with a control group 
receiving isotype control (IgG1) antibody. A significant reduction in 
CD4+CD25+Foxp3+ cells in blood from anti-CD25 treated mice was observed (Fig. 30a) 
at day 8 p.a.. No significant difference in clinical disease was found between the two 
groups (Fig. 30b). Some stronger activation of microglia and astroglia was found, 
however, in PC61/DT double-treated animals compared to DT-treated oDTR mice (Fig. 
27b,c), probably indirectly caused by peripheral Treg cell depletion. However, neither 
H/E nor anti-CD3-stained sections revealed any lymphocyte infiltration or perivascular 
cuffs in both anti-CD25 and control-treated diseased CNS (data not shown). To test 
whether ablation of Treg cells led to sub-clinical activation of myelin-specific T cells 
lymphocytes LN cells from the two groups were stimulated in vitro with the major 
myelin proteins. Yet, also in this assay we did not detect any response towards myelin 
antigen (data not shown). Taken together, we could not find evidence for tolerance 
induction through antigen released by dying ODCs. Also, removing Tregs transiently 
during the course of induced demyelination did not lead to development of neither anti-
CNS autoimmunity nor priming of myelin-specific T cells. 
 
Absence of IGF-1 signaling on ODCs does not results in major myelin 
abnormalities 
 
To study the role of the IGF-1 pathway in mature ODCs we developed a novel mouse 
model (oIGF1R, Fig. 31a) by crossing a mouse strain carrying a loxP-flanked 3rd exon 
of the IGF1R (IGF1Rfl/fl, generated by our collaborator Jens Brüning) to the MOGi-
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Cre strain [89, 157]. The third exon of the IGF1R gene contains the region most 
important for ligand binding and its absence has been shown to incapacitate the receptor 
[102]. Since the deletion of the receptor in oIGF1R mice is restricted by the late 
expression of MOG, this model is intended to circumvent the developmental 
myelination deficits that have been described for conditional Cre-driven IGF1R ablation 
restricted by the earlier Olig1 or PLP promoters [101]. Accordingly, histological 
analysis of the CNS of oIGF1R-/- mice with LFB-PAS staining and with Iba1- and 
GFAP-specific antibodies did not reveal any major CNS anomalies compared to 
controls (Fig. 31b). Also, oIGF1R-/- mice compared to C57/Bl6 mice or littermate 
controls did not show any motor or behavioural abnormalities by composite motor test 
performed over the course of 1 month (Fig. 31c). To further investigate possible myelin 
abnormalities in our animal model, we analyzed CNS lysates of oIGF1R-/- and control 
mice at 3, 5, and 9 months of age by immunoblotting. However, we could not find any 
difference in the protein levels of MOG, MBP and PLP (Fig. 32a,b,c,d). Also, oIGF1R-
/- animals did not show differences in ODC density in any CNS area analyzed (Fig. 
32e). Accordingly, NG2 protein levels, indicative of number and activation state of 
OPCs, did not differ at 3, 5, and 9 months of age when compared to hemyzigous 
oIGF1R-/+ (IGF1Rfl/+, MOGi-Cre+) and wild type IGF1R+/+ control mice (Fig. 32f). 
However, at 9 months of age the brain/body weight ratio resulted significantly higher in 
male oIGF1R-/- mice compared to control oIGF1R+/+ mice (Fig. 33a). Nonetheless, 
female oIGF1R-/- mice did not display any brain/body weight ratio difference (Fig. 
33b). 
Impaired remyelination in oIGF1R-/- CNS following cuprizone intoxication 
 
As already mentioned, cuprizone intoxication results in increased IGF-1 production in 
affected CNS areas, and IGF-1 over-expression in situ seems to protect ODCs from 
death and to increase remyelination [106]. To test demyelination and ODC survival in 
our model we thus fed oIGF1R-/-, oIGF1R-/+ and oIGF1R+/+ ad libitum for 6 weeks 
with cuprizone and followed weight loss over the whole period. Interestingly, oIGF1R-
/- mice displayed less weight loss in the first weeks followed by a slightly impaired 
weight gain in the second half of the feeding period (Fig. 34a). Microglia numbers were 
increased in oIGF1R-/- and oIGF1R-/+ animals 3 weeks p.a. as shown by FACS and 
histological analysis (Fig. 34b,c). LFB-PAS stainings in the corpus callosum did not 
62 
 
reveal huge differences in myelin status among experimental groups (Fig. 35). To 
further investigate myelin phenotype in cuprizone-fed animals, we sacrificed oIGF1R-/-
, hemizygous and wt animals after 3 and 5 weeks of intoxication and analyzed CNS 
lysates by immunoblotting using PLP- and MOG-specific antibodies. A general 
decrease in PLP expression compared to normally fed mice was evident at both time 
points, but no significant differences could be detected between cuprizone-fed oIGF1R-
/- and control mice (Fig. 36a,b). However, demyelination seems to be slightly enhanced 
in the CNS of oIGF1R-/- mice (Fig. 36a,b). Analysis of NG2 protein levels revealed 
increased accumulation of this OPC marker specifically in oIGF1R-/- after 3 weeks of 
cuprizone feeding (Fig. 36c). On the opposite, at the end of the intoxication period NG2 
levels appeared significantly lower in oIGF1R-/- compared to controls (Fig. 36d). 
Finally, to assess the number of ODCs along the intoxication period, sagittal CNS 
sections were stained with ASPA-specific antibodies and ASPA+ cells were counted in 
cerebellum (data not shown) and corpus callosum regions (Fig. 36e). While no 
difference could be detected among the different groups 3 weeks p.a., ODC density was 
much lower in oIGF1R-/- and oIGF1R-/+ animals after 5 weeks of toxin feeding (Fig. 
36e). Thus, even though cuprizone administration did not result into grossly different 
myelin abnormalities in oIGF1R-/-  compared to wt control mice, absence of IGF1R in 
oIGF1R-/- mice or reduction of receptor expression in oIGF1R-/+ animals lead to a 
decreased ODC density under demyelinating conditions.  
 
MOG-immunized  oIGF1R-/- mice show lower disease incidence and disabilities 
compared to controls        
 
As already mentioned, the role of IGF-1 in the context of EAE is largely controversial 
[107, 109, 112, 121, 123]. To better investigate the role of this signaling pathway in 
ODCs under inflammatory autoimmune conditions, we immunized oIGF1R-/- and 
littermate controls with MOG35-55 in CFA (PT at d 0 and +2). Surprisingly, oIGF1R-/- 
mice showed in all experiments a significantly lower disease score and a lower 
incidence (Fig. 37a,b). Also, clinical amelioration at beginning and during the chronic 
phase of EAE was intrinsic for mice developing the disease (Fig. 37c). However, no 
difference in disease onset and average disease severity could be observed (Fig. 37b). 
Histological analysis of brain samples from experimental and control animals did not 
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reveal gross  differences between oIGF1R-/- and control mice, both in chronic (1 month 
p.i., Fig. 38a) and acute phase of EAE (disease onset, data not shown). Nonetheless, in 
some sample we found evidence of increased microglia activation (Iba1-specific 
stainings, Fig. 38a). Also, western blot analysis of CNS lysates 1 month p.i. revealed 
decreased gliosis in the CNS of IGF1R-/- mice (Fig. 38b). Flow cytometry analyses of 
CNS inflammatory infiltrates did not reveal consistent differences between oIGF1R-/- 
and controls (data not shown). However, analysis of microglia/macrophages revealed a 
relative decrease in MHC-II expression in, regardless of disease severity (Fig. 38c), and 
a significant reduction in CD44 and CD95 expression in oIGF1R-/- compared to control 
animals (Fig. 38d). To further investigate myelin and ODC status during autoimmune 
inflammation, we immunoblotted CNS lysates using MBP- and MOG-specific 
antibodies and found these protein levels slightly reduced in the CNS of oIGF1R-/- 
mice compared to controls (Fig. 39a). Surprisingly, we found significant reduction in 
ODC density in the corpus callosum of MOG-immunized oIGF1R-/- animals, both at 
peak disease and in the chronic phase, but in no other affected brain region (Fig. 39b,c). 
Hemizygous animals displayed a similar reduction in ODC density in the corpus 
callosum (Fig. 39c). Also, analysis of NG2 protein levels revealed increased OPC 
accumulation and activation in the CNS of oIGF1R-/- animals (Fig. 39d). Altogether, 
deletion of IGF1R on mature ODCs resulted in significantly increased protection and 
amelioration of EAE clinical signs; however, only minor histopathological changes in 
myelin and microglia/macrophages activation could be observed. On the other hand, 
local variations in ODC density and overall increase in progenitor markers seem to 
indicate an higher susceptibility of ODCs to inflammation in MOG-immunized 
oIGF1R-/- animals. 
 
A novel mouse model to quantify in vivo variations in myelin content 
 
In order to follow the in vivo dynamics of demyelination and remyelination, we have 
generated a mouse model (oLucR) in which luciferase expression is restricted by Cre 
expression to mature ODCs. Once the genetic locus of luciferase is recombined, oLucR 
mice express the reporter gene under the control of an ubiquitous β-actin promoter [158] 
(Fig. 40a). Since ODCs selectively express luciferase, induced ODC death and 
demyelination should result into decreased bioluminescence; also, demyelination-
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triggered differentiation of OPCs should provide a readout of remyelination as new 
MOG-expressing ODCs repopulate the lesion and express luciferase for the first time. 
The mice were shaved, anesthetized and quantitatively measured in an ultrasensitive 
IVIS machine (Xenogen) after i.p. injection of 150 ng/Kg of luciferin (Fig. 40b). The 
average photon-per-second recording over the full kinetics of luciferin/luciferase 
reaction was used as readout per mouse, per measurement. Besides CNS-specific 
luminescence, unspecific photon emission was also detected from non-CNS areas 
(especially liver, tail, and paws as in [158]). Thus, in every experiment bioluminescence 
signals were recorded from the whole animal as well as from specific areas of interest as 
brain and spinal cord (Fig. 40b). Continuous measurements of oLucR mice over 1 
month showed no significant changes in basal bioluminescence over time, indicating 
that luciferase expression remains stable in adult animals (data not shown).  
 
Cuprizone- and DT-mediated ODC death results into increased bioluminescence in 
oLucR mice 
 
To initially test the reporter system, oLucR mice were normally- or cuprizone-fed for 6 
weeks and bioluminescence changes recorded 3 times a week over the whole period. 
Since cuprizone intoxication results into specific ODC death in the corpus callosum, we 
expected a progressive decrease in bioluminescence along the feeding period. 
Surprisingly, IVIS measurements revealed a progressive increase in luciferase 
expression during the intoxication period specifically in toxin-fed oLucR mice. This 
increase reached its peak around 5 weeks p.a., and decreased progressively after 
removal of cuprizone from the diet (Fig. 40c). 60 days after starting the feeding we 
analyzed luciferase expression in CNS lysates through a luminometer assay and ex vivo 
by luciferin-bathed brain slices, but could not find any significant difference between 
cuprizone- and normally-fed mice, in concordance to the in vivo measurement (data not 
shown).   
Next, we wanted to test the effects of massive and diffuse ODC death on the 
bioluminescence readout in our model. Thus, we crossed oLucR mice to the oDTR 
strain, and injected the resulting oLucR/DTR animals and oLucR control with 200 ng of 
DT daily for a week. As expected, oLucR/DTR mice developed progressive motor 
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impairment starting 5 weeks p.a. (Fig. 41a). Surprisingly, bioluminescence recordings 3 
times a week did not reveal any decrease in luciferase signal. Rather, we could observe 
two different periods of increased bioluminescence in DT-treated oLucR/DTR mice: the 
first, during and shortly following the administration period of DT; the second, 6 to 7 
weeks p.a. (Fig. 41b). In vitro analysis of CNS lysates 7 weeks p.a. revealed increased 
expression of luciferase in cerebellum and brain stem (Fig. 42a). Accordingly, luciferin-
bathed ex vivo brain slices showed predominant luciferase expression into these myelin-
rich areas (Fig. 42b).  RNA analysis of CNS samples during the first peak of 
bioluminescence showed decrease in MOG expression, and increase in the OPC marker 
NG2 in oLucR/DTR compared to oLucR control mice (Fig. 42c,d). To further 
investigate this unexpected increase in photon signal we then analyzed the expression 
level of β-actin, which is regulated by the same promoter controlling luciferase 
expression. Our data shows that β-actin level were increased in DT-treated oLucR/DTR 
compared to oLucR control mice (Fig. 42e). 
MOG-immunized oLucR animals show increased bioluminescence around disease 
onset 
 
Surprisingly, induced ODC death in the oLucR model did not result in decreased 
bioluminescence (Fig. 40c, 41b). Rather, IVIS analyses of oLucR mice revealed sudden 
increases in photon signal from the damaged CNS concomitant to demyelination and 
OPC recruitment, and most specifically in heavily affected areas as cerebellum and 
brain stem (Fig. 42a,b,c,d). Hence, we wanted to test the dynamics of bioluminescence 
over the course of EAE, in which ODCs die sparsely and demyelination is more 
prominent in the spinal cord and brain stem areas [21]. oLucR animals were immunized 
with MOG in CFA and analyzed in the IVIS machine every other day to follow 
bioluminescence changes. As control served not-immunized oLucR animals. After a 
transient and brain-specific increase in bioluminescence at day 2, luciferase signal 
unexpectedly peaked around disease onset by 12-fold (Fig. 43a,b). Following this 
sudden increase, bioluminescence returned to lower levels, although brain signal 
remained higher than in the pre-induction phase. CNS ex vivo analysis by luciferin-
bathed slices and in vitro analysis by luminometer assay revealed accumulation of 
luciferase in spinal cord and brain stem 1 month p.a. in EAE-induced animals (Fig. 
43c,d). Nonetheless, it is known that during the course of EAE the permeability of the 
BBB is increased (Fig. 18d). To exclude that the observed in vivo bioluminescence 
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changes would result from increased permeability of the BBB and higher luciferin 
influx in the CNS, we immunized oLucR animals with MOG in CFA and sacrificed 
mice every other day starting from day 5. Ex vivo brain slices bathed in luciferin showed 
increased expression in mice showing clinical disease (Fig. 44a) and the 
bioluminescence pattern recapitulated the one observed in vivo (Fig. 43a). We then 
tested the possible effects of PT on bioluminescence, as the toxin is supposed to 
transiently open the BBB aiding the development of a self-immune response [159, 160]. 
Hence, we injected oLucR animals with PT and recorded bioluminescence changes over 
time compared to BSA-injected animals. PT resulted in a low and transient increase in 
luciferase signal (Fig. 44b), which was comparable to the first bioluminescence increase 
as detected in the EAE experiment (Fig. 42a). Thus, the strong luciferase signal 
recorded around disease onset is an intrinsic in vivo characteristic of ODCs under 
immune attack. To further investigate ODC status at EAE onset, we immunized and 
sacrificed oLucR animals at day 11 p.i.. RNA analysis revealed decreased ODC markers 
such as MOG and Olig1, and a strong increase in stem cell and OPC markers as NG2 
and Nestin (Fig. 45a,b,c,d). β-actin level was strongly increased specifically in the 
spinal cord of oLucR animals induced with EAE (Fig. 45e).  
 
Antibody-mediated demyelination in organotypic slice cultures derived from 
oLucR mice 
 
Induced ODC death and demyelination in the oLucR model resulted in a surprising in 
vivo increase in ODC-specific luciferase signal under different conditions (Fig. 40c, 
41b, 43a). To investigate the oLucR system without confounding in vivo factors, we 
thus worked with cerebellar organotypic slice cultures derived from neonatal mice (see 
Material and Methods). Slices were kept in culture with the addition of luciferin and 
imaged in the IVIS machine every other day (Fig. 46a). As demyelinating method, 
antiMOG and complement were added to the culture for 48 hours and then washed out 
with fresh medium. Preliminary analysis of bioluminescence in these cultures showed a 
relative increase in bioluminescence in demyelinated slices from oLucR slice compared 
to oLucR untreated slices (Fig. 46b). 
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Figure 14 
(a) The oDTR model: a mouse strain carrying a Cre-inducible diphtheria toxin receptor 
(iDTR) is crossed to a mouse strain expressing the Cre recombinase specifically in 
ODCs (MOGi-Cre). The double transgenic animals (oDTR) express the DTR on the 
surface of ODCs, which are thus rendered susceptible to DT. Upon injection of DT into 
such mice, OODCs die and demyelination iinitiated.  (b)  Scheme of the DT-induced 
death mechanism. The toxin binds to its receptor and is cleaved by a protease into its 
active components. After internalization and pH decrease, the A subunit is transferred 
by the B subunit in the cytosol where it enzymatically inactivates the elongation factor 2 
(EF2). 
. 
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Figure 15 
(a) oDTR clinical presentation: oDTR and control mice (MOGi-Cre or iDTR) were 
injected with 200 ng DT over a course of 7 days. In addition, a control group of oDTR 
mice received 200 ng of BSA over the same period of time. The animals were scored by a 
RotaRod and a grid walk motor tests. Weight of animals and tremor observed during the 
motor tests were recorded. The means of weight, tremor and motor assays measurements 
were combined in one representative composite score. (b) oDTR animals were treated 
with DT and sacrificed at the indicated time points. Nissl staining of the pons is shown. 
Magnifications in control and 1 week (wk) samples show condensed cytoplasm and shrunk 
nuclei after DT application in oDTR mice. Scale bar, 50 µm.  
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Figure 16 
Electron micrographs of brain stem sections show a normal-appearing 
ODC in the control mouse (left) compared to a moribund, densely-
vacuolated ODC in the DT-treated oDTR mouse (right). Samples were 
collected 14 days p.a.. Scale bar, 2 µm.  
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Figure 17 
(a) oDTR and control mice were treated with DT and sacrificed at indicated time points. 
CNS sections were stained with ASPA-specific Ab and positive cells were manually 
counted. The mean ratio between cell density in oDTR versus control mice is shown, ± 
s.e.m. (n=3, 4 sections per animal). (b) Sketch diagram illustrating a sagittal section of a 
murine brain. Areas analyzed and relative endpoint percentages of glial cells (7 weeks p.a. 
compared to control) are shown (b) oDTR mice were treated with 200 ng daily DT for a 
week. At reported time points p.a. brain sections were stained for the mature ODC-specific 
protein ASPA. Here we show the progressive disappearance of ODC nuclei from the 
striatum of DT-treated oDTR animals. Scale bar, 200 µm. (d) CNS sections were stained 
for H/E, PLP and LFB/PAS. For H/E and LFB/PAS mice were sacrificed 6 weeks p.a., for 
PLP staining 4 weeks p.a. Shown are magnifications of spinal cord (H/E and LFB/PAS) 
and striatum (PLP). Scale bar for H/E and LFB/PAS stainings, 100 µm. Scale bar for PLP 
staining, 50 µm. (e) oDTR and control mice were treated with DT and brain sections 
stained at different time points p.a. for the myelin protein PLP. Scale bar, 50 µm.   
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Figure 18 
(a) oDTR mice were sacrificed at indicated time points, RNA isolated from the spinal 
cord and analyzed by RT-PCR for PLP and MAG expression. Bar graphs indicate mean 
values relative to control ± s.e.m. (n=3).  (b) oDTR mice were sacrificed at indicated 
time points and brain lysates analyzed by immunoblotting against MBP and MOG. Bar 
graphs indicate mean values ± s.e.m. (n=3). (c) Electron micrographs of cerebellum 
from DT-treated control and oDTR mice show groups of normal-appearing myelinated 
axons in control brain (left) compared to demyelinated axons (asterisks), smaller 
vacuoles (arrows) and larger edematic areas (arrow heads) in material from oDTR mice 
(right).  Samples were collected 7 weeks p.a., scale bar 1 µm. (d) Evans blue analysis 
shows no difference in BBB integrity between oDTR and control animals 1 week after 
DT treatment. MOG/CFA immunized animals were used as positive, untreated animals 
as negative control.  
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Figure 19 
(a) oDTR/control animals were injected with DT and sacrificed at indicated time 
points. Representative NF-immunostained sections from cerebellum are shown. 
Scale bar, 50 µm. (b) DT-treated oDTR and control mice were sacrified at indicated 
time points p.a. and brain sections were stained with Fluoro-Jade C. Positively 
stained cells were quantified in the indicated areas (n=3). (c) Mice were treated with 
DT and sacrificed 1 week p.a.. CNS samples were collected and stained for TUNEL 
(green) and for the neuronal marker NeuN (red). Colocalizations of TUNEL and 
NeuN staining are shown in white. Shown is cerebellum, scale bar 20 µm. On the 
right, inlets show 10x magnification of a double-positive neuronal cell.  
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Figure 20 
 (a) DT-treated oDTR and control mice were sacrificed at indicated time points p.a. 
and brain sections immunostained for NG2 in the indicated areas. Scale bar, 50µm. (b) 
oDTR and control mice were sacrificed at indicated time points and brain lysates 
analyzed by immunoblotting against NG2 and Vinculin. Bar graphs indicate mean 
values relative to control ± s.e.m. (n=3). (c) DT-treated oDTR and control mice were 
sacrificed 5 weeks p.a. and corpus callosum samples were investigated by TEM. Shown 
is a scattergram of g-ratios in relation to axonal diameter. Average g-ratio in oDTR 
animals was 0.7967 ± 0.0055 compared to 0.7536 ± 0.014 in control animals, 
p<0.0001. 
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Figure 21 
 (a) Sections from dcLNs of DT- and BSA-treated oDTR mice were stained with OilRedO 
(ORO) 3 weeks p.a. Arrow indicates representative ORO+ cells. Scale bar, 20µm. (b) 
Quantification of ORO+ cells in dcLNs and inguinal LNs of DT- and BSA- treated oDTR 
animals, 3 weeks p.a. (data representative of 4 mice per group. Mean values and s.e.m.. 
***, P<0.001, two tailed Student’s t test). (c) oDTR and control mice were treated with 
DT and  sacrificed 1 and 2 weeks p.a.. Tissue lysates of lumbar LNs were analyzed by 
immunoblotting using antibodies specific for Vinculin (Vinc, loading control), MBP, and 
MOG. Total CNS extract was used as a positive control (160 µg of oDTR and control 
extracts and 80 µg CNS extract were loaded). Arrows indicate expected molecular 
weights for MOG protein and MBP isoforms. (d) Flow cytometric analysis of antigen 
leakage as detected by myelin-specific T cells. 107 CFSE-labeled 2D2 T cells were 
injected into oDTR mice 1, 2, and 3 weeks (wks) p.a. and recovered four days later. As 
controls served C57BL/6 (B6) mice either untreated (bottom, center and right) or 
immunized with MOG35-55 in CFA (bottom, left).  
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Figure 22 
(a) oDTR/IiMOG mice as well as MOGi-Cre/IiMOG controls were injected with 
25ng/g DT per day from d -3 to d 0. At d 0 CFSE-labeled 2D2 cells (CD90.1) were 
transferred into the CD90.2 oDTR/IiMOG and control mice. PT was applied i.p. at d 
0 and 2 followed by an agonistic mAb against CD40 (30 µg at d 5). Five days after 
transfer cells from axillary and inguinal LNs were analyzed by flow cytometry. As 
positive control served animals treated the same way and expressing IiMOG in all 
cells (del-Cre/IiMOG, top left). (b) Cells were isolated from DT-treated oDTR and 
control animals 7, 14, and 30 days p.a and stimulated in culture with OVA, PLP, 
MBP, and MOG peptide with or without CD28-specific antibody. For positive control, 
cells were isolated from LNs of B6 mice 9 days after immunization with MOG35-55 in 
CFA and stimulated in culture with the same proteins (***, P<0.001). (c) oDTR and 
control animals were treated with DT for 1 week and subcutaneously injected with 
KLH/CFA or MOG35-55/CFA (d) with additional i.p. injection of PT (right). 9 days 
post immunization animals were sacrificed, cells isolated from lymph nodes, and 
restimulated in vitro with KLH and MOG35-55, respectively, with or without CD28 co-
stimulation. Addition of OVA and ConA served as negative and positive control (mean 
and s.e. of 3 mice per group). 
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Figure 23 
(a) Flow cytometric analysis of cells isolated from the CNS of oDTR and control animals 1 
week (left) and 6 weeks (right) p.a.. Indicated are gates and percentages of cells in the 
respective gate for invading cells (CD45hi CD11b-), macrophages (CD45hi CD11bhi), and 
microglia (CD45intCD11bhi). Data representative of two independent experiments, n=6. (b) 
oDTR and control mice were treated with DT and sacrificed at indicated time points. CNS 
sections were stained with Iba1-specific Ab and positive cells were manually counted. The 
ratio between cell density in oDTR versus control mice is shown (n=3, 4 sections per 
animal). (c) Brain sections from oDTR mice 5 weeks p.a. were stained with Iba1 antibody. 
Scale bar, 100 µm. (d) Brain sections of oDTR and control mice showing activated 
microglia/macrophages 4 weeks p.a. (microglia: MHCII-specific antibody, red; tomato-
lectin: green). Scale bar, 200 µm. 
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Figure 24 
(a) oDTR and control mice were treated with DT. Cells from the CNS were isolated, stained for 
CD45, CD11b, CD44 and analyzed by flow cytometry. Bar graph shows the percentages of 
microglia expressing CD44 (mean and s.e. of 3 mice per group). (b) oDTR and control mice 
were treated with DT and sacrificed at indicated time points. CNS sections were stained with 
GFAP-specific Ab and positive cells were manually counted. The ratio between cell density in 
oDTR versus control mice is shown (n=3, 4 sections per animal). (c) Histological sections from 
the CNS of indicated animals and bone marrow (positive control) were stained with antibody 
to CD3. Scale bar, 100 µm. (d) oDTR and control animals were treated with 400 ng DT at d0, 
2, 4, and 6. 50 days p.a. cells were isolated from the CNS, stained for CD45, CD11b, CD4, and 
CD8 and analyzed by flow cytometry. Absolute number of infiltrating CD4+ (left) and CD8+ 
(right) T cells are shown. Data are representative of two independent experiments (mean and 
s.e.m. of 5 mice per group). As positive and negative control served cells isolated from the CNS 
of oDTR animals 20 days post-immunization with CFA and MOG peptide (mean and s.e.m. of 3 
mice per group) and of untreated C57/Bl6 (B6) animals (mean and s.e.m. of 2 mice per group), 
respectively. ***, P<0.001. 
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Figure 25 
(a) Following a 5 months-treatment with a weekly dose of 50 ng DT, oDTR and control 
mice were sacrificed and LFB-PAS staining performed on slices. Shown is brain stem, 
scale bar 200 µm (n=3). (b) Mice were treated with one single dose of 50 ng DT and 
sacrificed 3 days later. Slices were Nissl-stained, pons is shown. Scale bar 200 µm (n=3). 
(c) Mice were treated as in (a) and slices were stained with Iba1-specific antibodies. 
Shown is cerebellum, scale bar, 100 µm  (n=3). (d) Flow cytometric analysis of cells 
isolated from the CNS of oDTR and control animals after 5 months of chronic ODC death.  
CD4+ and CD8+ T cells are gated from the CD11b- CD45hi population, CD4+ effector 
cells gated on CD44hi CD62Llow CD4+ total cells, CD8+ effector cells gated on  CD44hi 
CD62Llow CD8+ total cells. Bar graphs represent mean percentage of cells in the 
respective populations and s.e.m., n=6. 
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Figure 26 
 (a) oDTR and control mice were injected with DT and, after 4 weeks, with 
125I-labeled MOG-specific antibodies. Mice were sacrificed after 12 hours, 
perfused, and the CNS were analyzed for radioactive incorporation by use of a 
gamma-counter (n=2). (b) oDTR and control animals were treated i.p. with 
400 ng DT at  d0, 2, 4, and 6, and i.v. with 200 µg of either MOG-specific or 
NP-specific antibody at d14, 21 and 28 and scored as described in Fig. 15a. 
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Figure 27 
oDTR and control mice were treated with DT only or DT+ CD25-, MOG-, or 
CD40-specific antibodies  and sacrificed 7 weeks p.a.. CNS sections were stained 
with ASPA-specific (a), GFAP-specific (b) or Iba1-specific (c) Abs and positive 
cells were manually counted. The mean ratio between cell density in oDTR versus 
control mice is shown, ± s.e.m. (n=3, 4 sections per animal). 
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Figure 28 
(a) oDTR/2D2 and MOGi-Cre/2D2 mice were injected with DT 3 times (25 ng/g) and 7 d 
p.a. treated with CFA (d0) and PT (d0 and +2). Graphs show percentages of sick animals 
in the respective groups. Data were pooled from three independent experiments (n=32). 
(b) oDTR/2D2 and MOGi-Cre/2D2 mice were treated as in (a), shown is the EAE disease 
course. Data was pooled from three independent experiments (n=32). (c) oDTR and 
control animals were treated with 250 ng DT weekly and 2 animals per group received at 
d30, 37, and 44 p.a. 200 µg of agonistic CD40-specific antibody. Brain sections from 
these animals were stained with anti-Iba1 55 days p.a.. Shown is corpus callosum, scale 
bar 100 µm. (d) oDTR and control animals were treated as in (c), scoring as in Fig. 15a. 
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Figure 29 
(a) oDTR mice were treated with 200 ng DT or BSA daily for a week and then immunized 
with MOG35-55 in CFA on day 0. PT was injected at d0 and d2. Animals were scored as 
described in Methods section (Data representative of two independent experiments, 8 
mice per group. Shown are mean values and s.e.m.). (b) Disease incidence of 
CFA/MOG35-55-immunized animals with or without PT or DT application. (c) 
oDTR/IiMOG mice and MOGi-Cre/IiMOG controls were treated as described for 
tolerance induction. LN cells were stained for CD90.1 and CD4, and analysed by flow 
cytometry. Shown are cells gated on CD4+ cells. The percentages of cells lying in the 
CD90.1+ CD4+ and CD90.1- CD4+ gates are indicated.  
. 
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Figure 30 
(a) oDTR and control mice were treated with DT and at d1, 3, and 5 injected with 150 
µg of CD25-specific antibody or IgG isotype control. At day 8 blood was collected and 
stained for CD45, CD4, CD25, Foxp3 and analyzed by flow cytometry. Bar graph 
shows mean percentages and s.e.m. of Foxp3+CD25+ cells within the CD4+ 
population, n=9. (b) oDTR and control animals were treated as in (a). Scoring as in 
Fig. 15a. Data are relative to two independent experiments, n=10. 
. 
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Figure 31 
a) Mice carrying an IGF1R gene with the 3rd exon floxed (IGF1Rfl/fl) were crossed to 
mice expressing the Cre recombinase specifically in ODCs (MOGiCre). In the resulting 
offspring (oIGF1R-/-), Cre proteins recombine IGF1R locus in ODCs resulting in 
conditional KO of IGF1R. b) Histological analysis of 4 months old-oIGF1R-/- animals 
and WT control animals show no major abnormalities in oIGF1R-/- mice. Staining were 
performed with Luxol Fas Blue-Periodic Acid Schiff (LFB-PAS) and with antibodies 
specific for Iba1 (microglia) and GFAP (astrocytes). Scale bar, 250 µm. c) 3 months old 
oIGF1R-/- and control mice were tested as in Fig. 15a  up to 38 days.  
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Figure 32 
oIGF1R-/- and oIGF1R+/+ control mice were sacrificed at 3 (a) and 5 (b) months of age 
and CNS lysates analyzed by immunoblotting against MBP and MOG. Band intensity is 
shown, n=5. (c) oIGF1R-/- and controls were sacrificed at 9 months of age and CNS 
lysates immunoblotted with MOG- and (d) PLP- specific Abs. (e) oIGF1R-/- and control 
mice were sacrificed at 3 months of age and CNS sagittal sections stained with ASPA-
specific antibodies. ASPA+ cells were manually counted with Image J software. ODC 
density per brain region is shown (n=4 sections per region, per mouse). (f) CNS lysates 
from oIGF1R-/- and control mice of indicated ages were immunoblotted with NG2-specific 
antibodies. Shown are the band intensities relative to the oIGF1R+/+ controls.    
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Figure 33 
oIGF1R-/- and control mice were weighted and sacrificed at 3,7, and 9 months of 
age. Brain weight was measured, shown is brain/body weight ratio, n=7. Male (a) 
and female (b) average weights ± s.e.m. are displayed. * = p<0.05, Student’s T test.  
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Figure 34 
(a) oIGF1R-/-, oIGF1R-/+ and control mice were fed with 0.2% cuprizone for 6 
weeks and regularly weighted. Data were pooled from two independent experiments, 
n=10. (b) FACS analysis of cells isolated  from the CNS of cuprizone-fed mice, 3 
weeks p.a. (c) CNS sections from oIGF1R-/- and controls fed with cuprizone for 3 
weeks were Iba1-stained and positive cells quantified. 
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Figure 35 
Histological analysis of the splenium of the corpus callosum in cuprizone-fed 
oIGF1R-/- and control mice. Sagittal sections were stained with Iba1- and GFAP- 
specific antibodies, or stained with LFB-PAS. Above, samples from 3 weeks-treated 
animals, below, samples from 6 weeks treated animals. Scale bar, 200 µm. 
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Figure 36 
oIGF1R-/- and control mice were fed with 0,2% cuprizone and then sacrificed after 
3 (a,c) or 5 weeks (b,d).Brain lysates were immunoblotted using PLP- and MOG-
specific antibodies (a,b) or NG2-specific antibodies (c,d). As control served mice 
which did not receive cuprizone in the diet (no cuprizone). (e) oIGF1R-/- and 
control mice were sacrificed 3 and 5 weeks after cuprizone feeding and CNS sagittal 
sections stained with ASPA-specific antibodies. Number of ASPA+ cells was 
manually estimated with Image J software. ODC density per corpus callosum is 
shown (n=4 sections per region, per mouse).   
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Figure 37 
(a) oIGF1R-/-, oIGF1R-/+ and control animals were immunized with MOG35-55 in 
CFA and injected with PT on day 0 and day +2. Animals were scored for clinical 
signs of disease. Data pooled from 5 independent experiments.  (b) Summary table 
of 5 EAE experiments with clinical parameters of oIGF1R-/-, oIGF1R-/+ and 
control animals. oIGF1R-/- mice show lower incidence of clinical EAE. (c) The 
graph represents pooled EAE clinical scores as in (a). Only animals which 
developed clinical EAE are displayed.    
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Figure 38 
(a) oIGF1R-/- and control animals were immunized with MOG35-55 in CFA, and mice 
sacrificed 1 month p.i. CNS sagittal sections were analyzed by histology with 
Hematoxylin/Eosin (H/E), LFB-PAS, and with antibodies specific for Iba1 (microglia) 
and GFAP (astrocytes). Scale bar, 250 µm. (b) oIGF1R-/- and control animals were 
immunized with MOG35-55 in CFA, and sacrificed 1 month p.i. CNS lysates were 
immunoblotted using antibodies specific for GFAP. Band intensity is shown, n=5.  (c) 
oIGF1R-/- and control animals were immunized with MOG35-55 in CFA, CNS cells were 
isolated and stained for CD45, CD11b, and MHC-II. Analysis was performed by flow 
cytometry. Shown are percentages of MHC-II+ microglia/macrophages gated on 
CD45high-CD11b+ cells. Data are representative of two independent experiments. As 
negative control served cells isolated from the CNS of steady-state animals. (d) Mice 
were treated as in (c) and cells analyzed by flow cytometry using CD44- and CD95-
positive antibodies (n = 4, ***P < 0.001, **P < 0.001, *P < 0.05, Student’s t test.) 
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Figure 39 
(a) oIGF1R-/- and control animals were immunized with MOG35-55 in CFA, and mice 
sacrificed 1 month p.i. CNS lysates were immunoblotted using antibodies specific for 
MBP and MOG. Band intensity is shown, n=5. (b) EAE was induced in oIGF1R-/- and 
control mice, animals sacrificed 15 days and (c) 1 month p.i.; CNS sagittal sections were 
stained with ASPA-specific antibodies. ASPA+ cells were manually counted with Image 
J. ODC density per CNS region is shown (n=4 sections per region, per mouse). 
*=p<0.05, Student T test.  (d) oIGF1R-/- and control animals were immunized with 
MOG35-55 in CFA, and mice sacrificed 1 month p.i. CNS lysates were immunoblotted 
using antibodies specific for NG2. Band intensity is shown, n=5. *=p<0.05, Student T 
test.   
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Figure 40 
(a) oLucR mice originate from the crossing of MOGi-Cre mice with a strain carrying a 
Cre-inducible luciferase gene under actin promoter. Injection of luciferin results into 
bioluminescence production, which can be measured (b) in a ultrasensitive IVIS100 camera 
system after shaving and anesthetizing the animals. The Igor pro software allows the 
specific measurement of ROIs (region of interests), quantifying photon production from the 
whole animal (big rectangle) or from specific regions of the CNS (brain, red circle; spinal 
cord, small rectangle). (c) Cuprizone- and  normally-fed oLucR mice were measured for 
luciferase expression with the IVIS every 3 days along the course of the experiment. Before 
intoxication, mice were measured for 3 weeks to set the baseline luciferase expression 
(here depicted in red). Shown is the ratio of bioluminescence between cuprizone-fed and 
normally-fed (control) oLucR animals (n=5).  
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Figure 41 
(a) oLucR mice originate from the crossing of MOGi-Cre mice with a strain carrying 
a Cre-inducible luciferase gene under actin promoter. Injection of luciferin results 
into bioluminescence production, which can be measured (b) after shaving and 
anesthetizing the animals in a ultrasensitive IVIS100 camera system. The Igor pro 
software allows the specific measurement of ROIs (region of interests), quantifying 
photon production from the whole animal (big rectangle) or from regions of the CNS 
(brain, in the circle; spinal cord, in the small rectangle). (c) Cuprizone- and  
normally-fed oLucR mice were measured for luciferase expression every 3 days along 
the course of the experiment. Before intoxication, mice were measured for 3 weeks to 
set the baseline luciferase expression (here depicted in red). Shown is the ratio of 
detected bioluminescence between cuprizone-fed and normally-fed (control) oLucR 
animals.  
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Figure 42 
(a) oLucR/DTR and oLucR control mice were treated with DT and sacrificed 7 weeks 
p.a. Lysates from indicated brain regions were tested in a luminometer assay for 
luciferase expression. (b) Representative picture of a luciferin-bathed sagittal brain 
slice from DT-treated oLucR/DTR mice, 30 days p.a.. (c,d,e) oLucR/DTR mice and 
oLucR mice were treated with DT and sacrificed 9 days p.i. RNA was isolated from the 
CNS and RT-PCR for MOG, NG2 and Actin performed. Shown are expression values 
relative to control for the indicated brain regions, n=3. 
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Figure 43 
(a) oLucR mice were measured for luciferase expression in a IVIS machine and 12 days 
later immunized with MOG in CFA. Bioluminescence was monitored until 34 days p.i., 
shown is photon emission relative to not-immunized oLucR controls. Measurements from 
the whole animals and specific for brain and spinal cord regions are shown, n=5. Data 
representative of 2 independent experiments. (b) Clinical score of EAE as in (a). (c) oLucR 
animals were immunized with MOG in CFA (left) and sacrificed 35 days p.i. Brain slices 
and spinal cord tissues were bathed in luciferin and imaged in the IVIS machine. On the 
right, samples from untreated control mice. (d) oLucR mice were immunized with MOG in 
CFA and sacrificed 35 days p.i. Lysates from indicated brain regions were tested in a 
luminometer assay for luciferase expression, expression are shown relative to control 
tissue from not immunized animals. 
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Figure 44 
(a) oLucR animals were immunized with MOG in CFA and sacrificed at indicated time 
points p.i. Brain slices and spinal cord tissues were bathed in 150 µg/ml luciferin and 
imaged in the IVIS machine for 2’. Clinical score at the time of sacrifice is indicated. 
On the bottom, control mice remained untreated. Representative slices are shown. (b) 
oLucR mice were injected with 400 ng PT at day 0 and day 2 and imaged in the IVIS 
machine. Shown is bioluminescence relative to not-injected controls. 
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Figure 45 
oLucR mice  were immunized with MOG in CFA  and sacrificed 11 days p.i.. RNA was 
isolated from the CNS and RT-PCR for (a) MOG, (b) Olig1, (c) NG2, (d) Olig2, (e) 
Nestin, and (f) Actin performed. Shown are expression values relative to control for the 
different brain regions, n=3. 
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Figure 46 
(a) Cerebellar slices from P9 pups were kept in culture with the addition of 150 ug/ml 
luciferin and imaged in the IVIS machine every other day. (b) AntiMOG and 
complement or antiMOG alone as a control were added to the culture for 48 hours 
(red line in the graph) and then washed out with fresh medium. As negative control, wt 
mice cerebellar slices were used (Cntrl).  
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DISCUSSION 
 
Is ODC death the initial trigger of Multiple Sclerosis? 
 
MS is generally accepted to be an autoimmune disease with auto-reactive T cells 
sustaining a multifocal inflammatory demyelination. Recent descriptions of the disease 
have pointed towards the presence of at least four partially overlapping histological MS 
subtypes [161]. While Lucchinetti suggest that these subtypes correlate to different 
disease entities, Barnett and Prineas favor a view in which the types correspond to 
various stages along the disease course [68] with primary apoptosis of ODCs as 
common triggering event. To directly and systematically address the question whether 
ODC death could initiate an MS-like pathology in mice, we needed a system of induced 
ODC degeneration. One frequently used system is cuprizone-induced demyelination 
[162]. The latter suffers, however, from severe side-effects [163, 164] and its unknown 
mode of action makes data interpretation difficult. Investigation of anti-CNS immunity 
has been aided by the animal model experimental autoimmune encephalomyelitis 
(EAE). However, since this model uses active immunization against myelin or the 
transfer of myelin-reactive T cells to trigger the disease, it cannot shed light on the 
etiology of anti-CNS-immunity. Some attempts to investigate the triggering phase of 
MS involved the metabolic impairment of ODCs but did not result in pronounced 
autoimmunity, although scattered infiltrations of lymphocytes were found in the CNS 
[165-167]. In contrast to the scenario described by Barnett and Prineas, however, 
substantial ODC death was not observed in these models. To overcome all these 
limitations, we have developed a mouse model (oDTR, Fig. 14a) which allows us to 
selectively induce ODC death by targeted expression of a diphtheria toxin receptor 
(DTR) and injection of diphtheria toxin (DT) [129]. By ectopic expression of a DTR 
murine cells become sensitive to DT, which induces cell death by termination of protein 
synthesis (Fig. 14b). Thus, in contrast to other animal models of demyelination, the 
mechanism of DT is well-established [168] and genetically restricted to mature MOG-
producing ODCs [129]. In this respect, two almost identical mouse models of 
experimental DT-mediated ODC depletion were published in the literature and showed 
no lymphocyte infiltrations in the CNS [134, 135]. However, these models are not 
suitable to investigate the triggering phase of neuroinflammation as the inducer used in 
these studies –tamoxifen- was shown in the past to suppress autoimmunity including 
EAE [169]. 
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In our model we observed massive ODC death and progressive disruption of myelin 
tissue in all CNS white matter areas with progressive clinical signs like cachexia, ataxia, 
kyphosis, and tremor. Several other animal models described tremor as result of myelin 
defects within the cerebellar motorfunction control circuitry [165, 170-172] and we 
confirm this by detecting degenerating neurons in the cerebellum of treated mice. In 
addition, we found progressive gliosis and activation of microglia/macrophages shown 
by high MHC class II expression and upregulation of CD44 [173, 174] similar to other 
models of myelin damage [175-177]. Importantly, this strong activation resembles 
microglia reactivity in early-stage MS plaques as described [68, 178, 179]. 
Similar to observations in MS patients [136, 137], ODC death resulted in accumulation 
of myelin material in lumbar and dcLNs. These CNS-draining LNs are required for 
development of relapses and epitope spreading in EAE [46] and are thus candidate 
locations for activation of CNS-reactive lymphocytes. Nonetheless, following both 
acute and chronic DT-mediated ODC death we did not detect any significant T cell 
activation through myelin antigens and did not find any significant parenchymal or 
perivascular lymphocyte infiltrations.  
Because bystander activation has been for a long time discussed as mechanism 
triggering MS, we assessed whether induced ODC death acted in synergy with 
established activators of adaptive immunity to induce an MS-like disease. We applied 
CFA and PT, injected MOG-reactive T cells, depleted Treg cells, and treated the 
animals with anti-CD40 antibodies. Despite these strong biases towards eliciting an 
adaptive T cell-driven immune response, we did not find any sign of anti-CNS 
autoimmunity or any significant change in the course of the disease. Also the presence 
of demyelinating antibodies as found in MS did not facilitate lymphocytic infiltrates or 
altered disease development. Because none of our experiments showed autoimmune 
inflammation, we tested whether induced ODC death led to tolerance as described by 
one research group for cuprizone-treated animals [180]. Yet we could not find any 
evidence for tolerance induction in our model.  
However, myelin-specific 2D2 T cells showed weak proliferation in some DT/PT/anti-
CD40-treated oDTR/IiMOG animals and the incidence of EAE in DT/CFA/PT-treated 
2D2/oDTR was slightly (albeit insignificantly) higher compared to treated 2D2/control. 
Thus, although our data might support the notion of rare stochastic activation of the 
adaptive immunity following ODC death, our overall endeavour clearly failed to detect 
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a presence of T and B cells during ODC death remotely comparable to EAE or MS. 
Hence, even in our most biased experimental designs, activation of myelin-specific T 
cells following ODC death seems to be a minor stochastic event. However, we are 
aware of the limitations imposed by the use of a single mouse strain on a fixed genetic 
background (C57/Bl6). In order to confirm and extend our observations, we are thus 
currently backcrossing the oDTR system to a different genetic background, the SJL, and 
will repeat the same experiments of induced ODC death associated to different immune 
manipulations.  
 
As already mentioned, others have also tried to link pathologically modified ODCs with 
CNS inflammation. While some myelin alterations result in severe neural degeneration 
without development of inflammation [131-133] other lead to an inflammatory 
environment also involving invading lymphocytes. For instance, ODC-restricted 
deletion of Pex5 [165] results in diffuse neuronal death and CNS infiltrations by B and 
CD8+ T lymphocytes. Similar to these observations, mice over-expressing proteolipid 
protein (PLP) in ODCs show late-onset neuronal degeneration followed by an influx of 
CD8+ T cells into the brain parenchyma [166, 167]. In contrast to our system in which 
ODCs are killed rapidly through protein translation blockade [168], in both, the Pex5 
and PLP systems genetic alterations result in late-onset demyelination and neuronal 
death without pronounced effects on ODC survival. These compromised ODCs may 
signal their distress to the immune system and such a chronic trigger may lead to the 
described recruitment of cytotoxic T lymphocytes. Our data, on the other hand, clearly 
support the notion that ODC death per se does not represent a powerful activator of 
adaptive immunity.  
Along this line, these observations can be of interest regarding other disease entities 
presenting with ODC death, demyelination, and inflammation. In one such disease X-
linked adrenoleukodystrophy (X-ALD), mutations in the ABCD1 gene, a peroxisomal 
transporter, result in accumulation of saturated very long chain-fatty acid which leads to 
inflammatory CNS lesions comprising of macrophages, reactive astroglia, and T cells 
[181]. It is still unknown whether inflammation in X-ALD patients is cause or result of 
the characteristic demyelinating processes. Interestingly, for unknown reasons Abcd1 
mutations in mice [182-184] do not result in sustained inflammation of the CNS, while 
Pex5-mutant mice, also showing alteration of peroxisome metabolism, can be used as a 
model for the neuroinflammatory component of X-ALD. Also infectious agents were 
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suggested to play a role in the etiology of MS and investigated in animal models. 
Infection of mouse CNS with either mouse hepatitis virus (MHV) and Theiler’s murine 
encephalomyelitis virus (TMEV) results in activation of virus-specific T cells and 
killing of infected ODCs with subsequent demyelination [185, 186]. While MHV 
infection progresses into a chronic disease associated with inflammation, TMEV 
infection results in epitope spreading and consequent activation of myelin-reactive T 
cells [187]. Conversely, in the human during progressive multifocal 
leukoencephalopathy, reactivation of the JC virus in the CNS results in focal 
demyelinated lesions classically devoid of lymphocyte infiltrates [188], although some 
inflammatory forms have also been described [189].  
Taken together, we have addressed a hypothesis that has been postulated repeatedly, and 
we have excluded a large number of possibilities leading up to MS-like pathologies. 
Even though DT administration in oDTR animals resulted in histopathological changes 
resembling the early stage-MS lesions as described by Barnett and Prineas, our insult to 
the CNS does not lead up to the severe inflammation commonly described in late stage-
MS plaques [161] and other neuroinflammatory diseases. Thus, assuming that a 
multifactorial and heterogenous human disease as MS can really be modeled in animal 
experiments, our work shows that mere ODC death is not sufficient to trigger adaptive 
immune response. 
 
What is the role of IGF1R in mature ODCs? 
 
The IGF-1/IGF1R axis has been shown to influence OPC differentiation, myelination 
and repair [100, 106-108], and generally to act as a neuroprotective and pro-survival 
factor in the ODC lineage and in surrounding parenchymal cells [115] [117-119]. Even 
though ODC death per se does not represent an immunogenic event, ODC apoptosis 
remains a fundamental factor in the context of induced neuroinflammation and 
contributes substantially to disability development and progression [89]. Also, some 
genetic impairments which lead to chronic ODC stress eventually result in the 
activation of adaptive immune response [165-167], thus indicating a possible role of 
mature ODCs in influencing the immune system under physiological conditions and 
signaling their distress under pathological conditions [67]. Unfortunately, only one 
104 
 
study has so far addressed IGF1R function in late developmental ODC stages [101], and 
the literature still lacks a characterization of the role of IGF1R specifically for mature 
ODCs. Also, the IGF-1/IGF1R impact on ODC apoptosis and survival within 
inflammatory CNS lesions is utterly unclear. Published EAE studies are highly 
controversial and show contrasting treatment outcomes [107, 109, 112, 121, 123]. In 
these works, broad deletion of IGF1R from different cells or systemic administration of 
IGF-1 –with pleiotropic effects on several cell types- make data interpretation virtually 
impossible. To overcome these limitations we have developed the oIGF1R-/- model 
(Fig. 31a) in which IGF1R deletion is restricted to MOG-producing mature ODCs. 
Interestingly, while deletion of IGF1R on pre-mature ODCs was shown to affect myelin 
content and brain weight already in young animals [101], oIGF1R-/- mice appeared 
identical to their littermate counterparts in terms of myelination and ODC number until 
9 months of age (Fig. 31b, 32, 33b). Counterintuitively, in male oIGF1R-/- mice the 
brain/body weight ratio was significantly higher than in male control mice at 9 months 
of age (Fig. 33a).  
When immunized with MOG in CFA, oIGF1R-/- mice were surprisingly protected from 
the development of EAE (69% of sick animals among oIGF1R-/- mice, 85.7% in 
control animals, Fig. 37a,b). Also, among the animals displaying clinical paralysis, 
oIGF1R-/- mice showed an intrinsically ameliorated disease compared to littermate 
controls (Fig. 37c). Histological and western blot analyses did not reveal gross myelin 
differences among different genotypes; also, ODC density in the classically inflamed 
areas in EAE, spinal cord and brain stem, appeared the same in all experimental mice. 
Rather, we were able to detect a significant decrease in ODC density in the corpus 
callosum of oIGF1R-/- animals, both during the acute and the chronic phase of disease 
(Fig. 39b,c). This data is unexpected, as neuroinflammation in EAE is not prominent in 
the corpus callosum. Furthermore, NG2 protein levels, indicative of number and 
activation state of OPCs, were drastically increased in oIGF1R-/- (Fig. 39d) animals. 
Since OPC recruitment is a consequence of ODC death and demyelination [43], these 
data might indicate a higher susceptibility to damage of IGF1R-/- ODCs. Analogous 
indications come from experiments in other demyelinating paradigms. Cuprizone-fed 
oIGF1R-/- mice display a lower ODC density in the corpus callosum 5 weeks p.a., with 
NG2 level again strongly higher than in littermate control animals (Fig. 36d,e). Similar 
to what we observed following EAE induction, histological analysis of cuprizone-
intoxicated mice did not reveal gross differences among genotypes. Nonetheless, a 
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slight reduction in myelin content could be observed specifically in oIGF1R-/- mice, 
and microglia numbers were increased compared to oIGF1R+/+ controls (Fig. 36a,b 
and Fig. 35b,c).  
Thus, in accordance to the proposed anti-apoptotic and myelogenic function of IGF1R 
on cells of the ODC lineage [106, 113, 119, 190], we found indications of a higher 
mortality of ODCs in oIGF1R-/- compared to control animals. In order to confirm these 
indications, future analysis will directly address the rate of ODC death in oIGF1R-/- 
animals within lesions in EAE and cuprizone intoxication and quantify longitudinally 
OPC recruitment during demyelinating insults.  
Different hypotheses could be put forward to explain the surprising protection from 
EAE in oIGF1R-/- mice. In the first place, a higher number of dying IGF1R-/- ODCs 
might lead to protection from neuroinflammation by release of immunosuppressive 
apoptotic bodies [72] [191]. Interestingly, this hypothesis is consistent with the 
reduction in inflammatory markers such as CD95, CD44 and MHC-II in 
microglia/macrophages and with the decreased levels of GFAP displayed in EAE-
induced oIGF1R-/- mice (Fig. 38b,c,d). A detailed phenotypical analysis of 
microglia/macrophages would thus shed light on their possible anti-inflammatory role 
and explain the conundrum of the higher Iba-1 reactivity observed 1 month p.i. (Fig. 
38a). At the same time, EAE amelioration in oIGF1R-/- mice might result from indirect 
effects on the IGF-1/IGF1R axis within the CNS. For instance, absence of the receptor 
from ODCs may lead to increased IGF-1 uptake in surrounding cells -i.e. neurons-, thus 
protecting the latter from bystander death and impacting in turn the clinical score 
through a reduced motor impairment [115]. A quantitative analysis of neuronal death 
and functionality might shed light on this point. Also, IGF-1 has also multiple effects on 
endothelial cells, glia and CNS-invading inflammatory lymphocytes [125], but the 
plethora of biological effects derived from this hypothetical higher bioavailability of 
IGF-1 remain difficult to address.   
All together, we have described for the first time a deletion of IGF1R specifically in late 
myelinating ODCs, without involvement of OPCs [106, 113, 114, 121, 123]. 
Interestingly, IGF1R does not seem to exert important functions in ODCs in the steady-
state, not-inflamed CNS: both myelin content and ODC number were not reduced 
through this specific deletion. Most likely, the relevance of IGF-1 signaling decreases at 
the end of ODC differentiation, while it seems necessary for myelination and OPC 
106 
 
survival at earlier stages [190]. Nonetheless, non-physiological situations as cuprizone 
intoxication show impaired recovery in oIGF1R-/-. Thus, the importance of IGF1R in 
remyelination and ODC survival is highlighted by demyelinating experimental 
conditions and leads to lower ODC density and higher OPC recruitment. Also during 
EAE, slightly higher myelin loss, increased progenitor recruitment and lower ODC 
density in corpus callosum point toward a pro-survival function of IGF1R in ODCs. 
However, as oIGF1R-/- display a counterintuitive protection from EAE, data 
interpretation becomes complex. The absence of the receptor seems to be clinically 
beneficial only in the peculiar context of EAE, in which ODCs experience prolonged 
stress in a hostile inflammatory environment. Direct and indirect effects of the absence 
of IGF1R might account for the observed clinical amelioration and have been discussed 
above.  
Taken together, the function of IGF1R in mature ODCs during neuroinflammation 
remain controversial, both in EAE [107, 109, 112, 121, 123] and MS. In the latter, 
different studies showed an upregulation of different components of the IGF-1/IGF1R 
axis within and surrounding sclerotic lesions, again suggesting a role in inflammation 
and demyelination [120, 192]. Also, one clinical study has addressed the possible 
therapeutic effect of recombinant IGF-1 in MS, but showed no efficacy in ameliorating 
the disease [193]. Understanding the mechanism(s) protecting mice from inflammation 
following IGF1R deletion on ODCs (Fig. 37a-c) could thus potentially shed light on the 
controversial role of ODCs in neuroinflammation both in EAE and MS.  
 
What is the behavior of ODCs during demyelination? 
 
The use of visible and fluorescent light in engineered biological systems has brought 
great advantages to researchers since its first applications, as expression of reporter 
proteins allows in vivo noninvasive visualization of specific tissues and cells [194]. 
Working with ODCs under different demyelinating paradigms, we thus wanted to create 
a novel system allowing the in vivo quantification of myelin amount and ODC number. 
For this purpose, we have developed the oLucR mouse model in which β-actin-driven 
expression of a luciferase gene is restricted by Cre-lox recombination to MOG+ cells, 
thus mature ODCs (Fig. 40a). After being shaved and anesthetized, oLucR mice were 
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injected with luciferin leading to production of light within ODCs; photon detection was 
performed through an ultrasensitive CCD camera in a IVIS system. As luciferase is 
expressed by ODCs under an housekeeping promoter, we thought that the number of 
ODCs and the amount of myelin in oLucR mice would be proportional to the recorded 
bioluminescence. However, IVIS recordings of oLucR animals under different 
demyelinating paradigms produced unexpected results. During cuprizone-feeding, 
oLucR mice showed progressive increase in photon emission from the CNS, and a 
decrease in signal during the subsequent remyelination phase (Fig. 40c). DT-induced 
ODC death in oLucR/DTR mice also resulted in two periods of increased 
bioluminescence: the first, during the DT administration period, and the second, in the 
late phase of the disease, after development of clinical disabilities (Fig. 41b). Thus, 
even 60% of ODC depletion in all white matter areas (Fig. 17a,b) would not lead to a 
decreased CNS-specific bioluminescence in our in vivo system. Finally, when 
immunized with MOG in CFA, oLucR mice showed a transient signal increase after 
disease induction and a strong, sharp emission peak close to the beginning of clinical 
EAE (Fig. 43a). PT treatment alone, known to increase BBB permeability, resulted in a 
transient increase in photon signal, thus suggesting that variations in luciferin access to 
the CNS might partially contribute to the observed fluctuations (Fig. 44b). However, we 
cannot exclude a direct effect of PT on ODCs [195]. Ex vivo and in vitro analysis of 
freshly-cut brain slices and CNS protein extracts could confirm the bioluminescence 
changes observed in vivo in the EAE and DT paradigms, and increased photon emission 
could be observed in demyelinating cerebellar slice cultures, a system completely 
devoid of a classic neurovascular junction (Fig. 46b). Thus, bioluminescence variations 
in oLucR tissues appeared intrinsic to luciferase-expressing ODCs and could not be 
explained by a mere in vivo artifact. Interestingly, luciferase signal appeared stronger in 
highly-damaged CNS regions: bioluminescence increase was more prominent in the 
spinal cord and brain stem in EAE-induced animals, and in the brain stem and 
cerebellum of DT-treated oLucR/DTR animals (Fig. 42a,b, 43c,d). Counterintuitively, 
it appears that demyelinating insults would increase luciferase signal in the ODCs of 
oLucR mice.    
In the oLucR system, Cre-mediated recombination allows the expression of luciferase in 
MOG-expressing ODCs under the control of a β-actin promoter. Thus, an increased 
activity of this promoter would result in a higher number of luciferase molecules and in 
an increase in light emission. Even though β-actin has been traditionally considered as 
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an housekeeping gene, it has been recently shown that its expression can be 
substantially upregulated during cell proliferation, activation, and differentiation [196, 
197]. As already described, actin filaments in ODCs are mostly associated to CNP-1 
proteins, and are the main constituents of thinner membrane domains of the myelin 
sheath [19]. Actin molecules are among the major players in the plasticity of cell 
body/myelin structures; consequently, the β-actin gene and its product must be 
subjected to strong expression changes during development, cell reorganization and 
myelination. It seems likely that concomitantly to immune attack, intoxication or 
demyelination, ODCs surrounding experimental lesions may experience stress-related 
dynamics which result in a drastic increase in β-actin production and, as a consequence, 
increased luciferase expression. Accordingly, β-actin expression in EAE-induced 
oLucR and DT-treated oLucR/DTR mice was higher than in control mice (Fig. 42e, 
45f). However, transgenic luciferase expression in oLucR animals is restricted to mature 
MOG-expressing cells. Little is known about the in vivo plasticity of fully-mature, post 
mitotic ODCs regarding myelin organization and mobility. Different studies indicated 
that ODCs lack the ability to repair demyelinating lesions [91, 99-101].  Nonetheless, 
other observations seemed to prove that mature ODCs maintain some structural 
plasticity and are capable of extending their processes in an attempt to remyelinate 
naked axons [93, 97, 98]. Accordingly, we put forward an hypothesis in which ODCs 
within demyelinating lesions increase their plasticity and activation state starting to 
produce new myelin and/or reorganizing pre-existing sub-structures of the myelin 
sheath. These processes might account for the initial signal increase recorded in DT-
treated oDTR/oLucR animals, in which the sudden massive death of ODCs may lead to 
an increased activity in surviving cells, and for the sharp peak detected at the clinical 
beginning of EAE, in which ODCs experience a direct immune attack.  
Even so, it remains difficult to explain the absence of any decreased bioluminescence 
following massive demyelination. Most likely, the disappearance of luciferase 
molecules following ODC death is masked and compensated by increased gene 
transcription in surrounding, activated ODCs. Unfortunately, it is not easy to address 
this experimentally.  
Altogether, we failed to establish an in vivo animal model allowing quantification of 
myelin amount during demyelinating paradigms. However, some evidences exist that 
oLucR mice can provide an in vivo readout of diffuse remyelination. 6 weeks after DT-
treatment, a progressive increase in photon signal could be consistently observed in 
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oLucR/DTR (Fig. 41b). Since OPCs are massively recruited to demyelinated white 
matter areas of DT-treated oDTR mice until 4 weeks p.a. (Fig. 20a), this late peak could 
possibly represent a de novo transcription of luciferase from newly formed mature 
ODCs, which started expressing MOG around 2 weeks after initial recruitment [198]. 
Taken together, the counterintuitive increases in the bioluminescence of ODCs within 
demyelinating regions raises fundamental issues regarding mature ODC biology. The 
observed trends in photon signal clearly support an hypothesis in which mature ODCs 
would play an active role and increase their plasticity in response to different kinds of 
parenchymal stress. Thus, these observations might be an additional contribution to our 
renewed concept of biology and function of ODCs, not anymore a mere “holding glue” 
of the CNS.  
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ABBREVIATIONS 
 
ODC – oligodendrocyte 
CNS – central nervous system 
MS – multiple sclerosis 
EAE – experimental autoimmune encephalomyelitis 
BBB – blood brain barrier 
APC – antigen presenting cell 
LPS – lipopolysaccharide 
OPC – ODC precursor cell 
PNS – peripheral nervous system 
MMPs – matrix metalloproteinases  
NO – nitric oxide 
TCR – T cell receptor  
LN – lymph node 
dc – deep cervical 
CSF – cerebrospinal fluid 
Treg – regulatory T cell 
RR – relapsing remitting 
MRI – magnetic resonance imaging 
CFA – complete Freund’s adjuvant 
SVZ – subventricular zone 
DT – diphtheria toxin 
PBS – phosphate buffer saline 
HBSS – Hank’s balanced salt solution 
MEM – minimum essential medium Eagle 
dNTP – deoxyribonucleotide 
DTT – dithiothreitol 
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TEM – trasmission electron microscopy 
LFB-PAS – luxol fast blue-periodic acid Schiff 
H/E – hematoxylin and eosin 
CFSE – carboxyfluorescin succinimidyl ester 
NP – nitrophenyl-hapten 
PT – pertussis toxin 
BSA – bovine serum albumin 
mAb – monoclonal antibody 
p.a. – post administration 
p.i. – post immunization 
DTR – diphtheria toxin receptor 
X-ALD – X-linked adrenoleukodystrophy 
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